

Product Monograph
Including Patient Medication Information

Pr **BLENREP**

belantamab mafodotin for injection
Monoclonal Antibody Drug Conjugate
Lyophilized powder for solution
70 mg or 100 mg per single-use vial
For intravenous infusion
Antineoplastic agent
ATC Code: L01FX15

GlaxoSmithKline Inc.
100 Milverton Drive
Suite 800
Mississauga, Ontario
L5R 4H1

Date of Authorization:
2025-09-26

Control Number:

©2025 GSK group of companies or its licensor
Trademarks are owned by or licensed to the GSK group of companies

Recent Major Label Changes

N/A

Table of Contents

Certain sections or subsections that are not applicable at the time of the preparation of the most recent authorized product monograph are not listed.

Recent Major Label Changes	2
Table of Contents	2
Part 1: Healthcare Professional Information	4
1. Indications	4
1.1. Pediatrics.....	4
1.2. Geriatrics.....	4
2. Contraindications	4
3. Serious Warnings and Precautions Box	4
4. Dosage and Administration	4
4.1. Dosing Considerations	4
4.2. Recommended Dose and Dosage Adjustment	5
4.3. Reconstitution.....	12
4.4. Administration	13
5. Overdose	13
6. Dosage Forms, Strengths, Composition, and Packaging	13
7. Warnings and Precautions	14
General.....	14
Driving and Operating Machinery.....	14
Hematologic.....	14
Immune.....	15
Ophthalmologic.....	15
Reproductive Health	16
Respiratory.....	16
7.1. Special Populations	16
7.1.1. Pregnancy	16
7.1.2. Breastfeeding	17
7.1.3. Pediatrics	17

7.1.4.	Geriatrics	17
8.	Adverse Reactions	17
8.1.	Adverse Reaction Overview	17
8.2.	Clinical Trial Adverse Reactions	18
8.3.	Less Common Clinical Trial Adverse Reactions in <10% of patients	26
8.4.	Abnormal Laboratory Findings: Hematologic, Clinical Chemistry, and Other Quantitative Data	26
9.	Drug Interactions	28
9.4.	Drug-Drug Interactions	28
10.	Clinical Pharmacology	29
10.1.	Mechanism of Action	29
10.2.	Pharmacodynamics	29
10.3.	Pharmacokinetics	29
10.4.	Immunogenicity	32
11.	Storage, Stability, and Disposal	32
12.	Special Handling Instructions	33
Part 2: Scientific Information		34
13.	Pharmaceutical Information	34
14.	Clinical Trials	34
14.1.	Clinical Trials by Indication	34
	DREAMM-7: BLENREP in combination with bortezomib and dexamethasone in adult patients with multiple myeloma who have received at least one prior therapy	34
	DREAMM-8: BLENREP in combination with pomalidomide and dexamethasone in adult patients who have received at least one prior therapy including lenalidomide	40
16.	Non-Clinical Toxicology	45
Patient Medication Information		47

Part 1: Healthcare Professional Information

1. Indications

BLNREP (belantamab mafodotin for injection) is indicated in combination with:

- bortezomib and dexamethasone, for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
- pomalidomide and dexamethasone for the treatment of adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy, including lenalidomide.

1.1. Pediatrics

Pediatrics (<18 years of age): The safety and efficacy of BLNREP in children and adolescents less than 18 years of age have not been studied; therefore, BLNREP is not indicated for pediatric use.

1.2. Geriatrics

Geriatrics (≥ 65 years of age): No overall differences in safety or efficacy were observed between older patients (65 years and over) and younger patients (less than 65 years).

2. Contraindications

BLNREP is contraindicated in patients who are hypersensitive to this drug or to any ingredient in the formulation, including any non-medicinal ingredient, or component of the container. For a complete listing, see [6 Dosage Forms, Strengths, Composition, and Packaging](#).

3. Serious Warnings and Precautions Box

BLNREP can cause changes in the corneal epithelium which may result in ocular symptoms such as changes in vision and dry eyes. Severe visual impairment and/or corneal ulcers can occur. Ophthalmic exams should be conducted prior to each dose of BLNREP or more frequently as clinically indicated. If changes in vision or corneal signs are not observed at or before the sixth dose exam, the ophthalmic examination frequency may be reduced to approximately every 3 months and whenever clinically indicated. The examination includes visual acuity testing and slit lamp examinations by an eyecare professional. If ocular adverse reactions are noted, withhold BLNREP until improvement and resume, or permanently discontinue, based on severity. Ocular adverse reactions can recur after resuming BLNREP even if the dose is reduced (see [7 Warnings and Precautions](#), [8 Adverse Reactions](#) and [4 Dosage and Administration](#) for management guidelines for these adverse reactions).

4. Dosage and Administration

4.1. Dosing Considerations

- BLNREP should be administered under the supervision of physicians experienced in the treatment of multiple myeloma, in an environment with immediate access to emergency equipment and appropriate medical support to manage infusion-related reactions if they occur.

- BLENREP is for intravenous infusion only. **Do not** administer as a push or bolus dose.
- BLENREP is administered after dilution as an intravenous infusion over approximately 30 minutes (see [4.3 Reconstitution](#); [4.4 Administration](#)).
- Administration of BLENREP should be continued until disease progression or unacceptable toxicity.
- Dosing interruptions and/or dose reductions are required to manage adverse reactions such as ocular adverse reactions (see [4.2 Recommended Dose and Dose Adjustment](#)).

Recommended Supportive Ocular Care:

- Patients should have an ophthalmic examination (including visual acuity and slit lamp examination) performed by an eye care professional, prior to each dose of BLENREP or more frequently as clinically indicated. If changes in vision or corneal signs are not observed at or before the sixth dose, ophthalmic exam frequency may be reduced to approximately every 3 months, and whenever clinically indicated (see [7 Warnings and Precautions, Ophthalmologic](#)).
- Physicians should encourage patients to inform them of any ocular symptoms. Additionally, they should advise patients to administer preservative-free artificial tears at least 4 times a day beginning on the first day of infusion and continuing until completion of treatment as this may help to reduce ocular symptoms (see [7 Warnings and Precautions, Ophthalmologic](#)).
- For patients with dry eye symptoms, additional therapies may be considered as recommended by their eye care professional.

4.2. Recommended Dose and Dosage Adjustment

Recommended Dose

BLENREP is administered as part of a combination regimen with bortezomib and dexamethasone or pomalidomide and dexamethasone. Refer to [14 Clinical Trials](#) for details on doses and schedules of the drugs used in combination. [Table 1](#) presents the recommended starting dose schedule of BLENREP when administered in combination with bortezomib and dexamethasone. [Table 2](#) presents the recommended starting dose schedule of BLENREP when administered in combination with pomalidomide and dexamethasone.

The Product Monographs for drugs used in combination with BLENREP should be consulted before starting treatment.

Table 1 Recommended starting dose schedule for BLENREP in combination with bortezomib and dexamethasone

Combination regimen	Recommended starting dose schedule
With bortezomib and dexamethasone (BVd) (Cycle length = 3 weeks)	2.5 mg/kg administered once every 3 weeks in combination for the first 8 cycles, and then continued as a single agent until disease progression or unacceptable toxicity.

Table 2 Recommended starting dose schedule for BLENREP in combination with pomalidomide and dexamethasone

Combination regimen	Recommended starting dose schedule
With pomalidomide and dexamethasone (BPd) (Cycle length = 4 weeks)	Cycle 1: 2.5 mg/kg administered once Cycle 2 onwards: 1.9 mg/kg administered once every 4 weeks until disease progression or unacceptable toxicity

Special Populations

Pediatrics (<18 years of age): The safety and efficacy of BLENREP in children and adolescents less than 18 years of age have not been studied; therefore, BLENREP is not indicated for pediatric use.

Geriatrics (≥ 65 years of age): No initial dose adjustment is required for patients who are 65 years of age or over (see [10.3 Pharmacokinetics](#)).

Renal Impairment: No initial dose adjustment is required in patients with mild, moderate or severe renal impairment (eGFR < 30 mL/min) (see [10.3 Pharmacokinetics](#)).

Hepatic Impairment: No initial dose adjustment is required in patients with mild hepatic impairment (defined as total bilirubin greater than ULN to ≤1.5 x ULN and any aspartate transaminase [AST] or total bilirubin ≤ ULN with AST > ULN). There are insufficient data in patients with moderate hepatic impairment and no data in patients with severe hepatic impairment to support a dose recommendation (see [10.3 Pharmacokinetics](#)).

Dosage Adjustment

In both clinical trials, dose modifications due to adverse reactions were common. Adverse reactions with belantamab mafodotin in combination with bortezomib and dexamethasone, including ophthalmic examination findings, leading to dose reductions of any component of therapy occurred in 81% (n=197) of patients. The median number of weeks between doses of belantamab mafodotin increased over the course of the trial: 3.6 during the first 6 months; 4.7 during months 6-12; 9.5 beyond 12 months of therapy. See [Table 17](#). Adverse reactions with belantamab mafodotin in combination with pomalidomide and dexamethasone, including ophthalmic examination findings, leading to dose reductions of any component of therapy occurred in 95% (n=143) of patients. The median number of weeks between doses of belantamab mafodotin increased over the course of the trial: 4.1 during the first 6 months; 11.8 during months 6-12; 14.1 beyond 12 months of therapy. See [Table 21](#). The recommended dose modifications for the management of adverse reactions are provided in [Table 3](#) and [Table 4](#).

The recommended dosage modifications for ocular adverse reactions, based on ophthalmic examination findings, which includes corneal examination findings and changes in best-corrected visual acuity (BCVA) are provided in [Table 4](#). Ophthalmic exams should be performed by an eye care professional prior to starting BLENREP, before each dose of BLENREP, more frequently as clinically indicated, and promptly for new or worsening ocular symptoms. If changes in vision or corneal signs are not observed at or before the sixth dose, ophthalmic exam frequency may be reduced to approximately every 3 months, and whenever clinically indicated (see [7 Warnings and Precautions, Ophthalmologic](#)).

The treating physician should review the patient’s ophthalmic examination findings before each dose and determine the dosage of BLENREP based on the results of the ophthalmic examination (see [Table 4](#)). During the ophthalmic examination, the eye care professional should assess the following:

- Any corneal examination finding(s) and/or any change in BCVA.
- If there is a decline in BCVA, the relationship to BLENREP should be determined.
- The category grading for these examination findings and BCVA should be communicated to the treating physician.

Determine the recommended dosage modification of BLENREP due to ocular adverse reactions based on the worst finding in the worse affected eye. Worst finding should be based on either a corneal examination finding or a change in BCVA. The worst category grading for ophthalmic examination findings should be communicated to the treating physician by the eye care professional.

The corneal examination findings may or may not be accompanied by changes in BCVA. Note: One eye may be more severely affected than the other. It is important for physicians to consider not only corneal examination findings but also visual acuity changes and reported symptoms as they evaluate the need for dose delays and reductions.

Do not re-escalate the BLENREP dose after a dose reduction is made for ocular adverse reactions.

Table 3 Dose reduction schedule for BLENREP

	In combination with bortezomib and dexamethasone (BVd)^a	In combination with pomalidomide and dexamethasone (BPd)^a
Recommended starting dose schedule	2.5 mg/kg every 3 weeks in combination for the first 8 cycles, and then continued as a single agent	Cycle 1: 2.5 mg/kg administered once Cycle 2 onwards: 1.9 mg/kg administered every 4 weeks
Reduced dose/schedule level 1	1.9 mg/kg every 3 weeks	1.9 mg/kg every 8 weeks
Reduced dose/schedule level 2	N/A	1.4 mg/kg every 8 weeks

BVd = belantamab mafodotin with bortezomib and dexamethasone, BPd = belantamab mafodotin with pomalidomide and dexamethasone.

^a. Extended dosing intervals were observed during the clinical studies (see [14 Clinical Trials](#), [Table 17](#) and [Table 21](#))

Table 4 BLENREP dose modification guidelines for adverse reactions.

Adverse Reaction	Severity ^a	Combination with BVd or BPd	Recommended dose modifications ^b
<p>Ocular adverse reactions (see 7 Warnings and Precautions, Ophthalmologic)^c</p>	<p>Mild (Grade 1) <i>Corneal examination finding(s)</i> Mild superficial punctate keratopathy with worsening from baseline, with or without symptoms.</p> <p><i>Change in BCVA</i> Decline from baseline of 1 line on Snellen Equivalent visual Acuity.</p>	<p>BVd/BPd</p>	<p>Continue BLENREP at current dose per the judgment of the physician with close direct monitoring of the patient’s clinical status.</p>
	<p>Moderate (Grade 2) <i>Corneal examination finding(s)</i> Moderate superficial punctate keratopathy, patchy microcyst-like deposits, peripheral sub-epithelial haze, or a new peripheral stromal opacity.</p> <p><i>Change in BCVA</i> Decline from baseline of 2 or more lines (and Snellen Equivalent Visual Acuity not worse than 20/200).</p>		<p>BVd/BPd</p>

	<p>Severe (Grade 3) <i>Corneal examination finding(s)</i> Severe superficial punctate keratopathy, diffuse microcyst-like deposits involving the central cornea, central sub-epithelial haze or a new central stromal opacity.</p> <p><i>Change in BCVA</i> Decline from baseline of 3 or more lines (and Snellen Equivalent Visual Acuity not worse than 20/200).</p>	<p>BVd/BPd</p>	<p>Withhold BLENREP until improvement in both corneal examination findings to mild severity and change in BCVA to decline of 1 line, or better. Resume treatment at reduced dose level 1 as per Table 3.^d</p>
	<p>Corneal Epithelial Defect or Change of BCVA 20/200 or worse (Grade 4) <i>Corneal examination finding(s)</i> Corneal epithelial defect.^e</p> <p><i>Change in BCVA</i> Decline to Snellen Equivalent Visual Acuity of worse than 20/200.</p>	<p>BVd</p>	<p>Withhold BLENREP until improvement in both corneal examination findings to mild severity and change in BCVA to decline of 1 line, or better. Resume treatment at reduced dose level 1 as per Table 3, at the discretion of the physician.</p> <p>For symptoms that are unresponsive to appropriate management, consider permanent discontinuation of BLENREP.</p>
		<p>BPd</p>	<p>Withhold BLENREP until improvement in both corneal examination findings to mild severity and change in BCVA to decline of 1 line, or better. Resume treatment at reduced dose level 2 as per Table 3, at the discretion of the physician.</p> <p>For symptoms that are unresponsive to appropriate management, consider permanent discontinuation of BLENREP.</p>

Thrombocytopenia (see 7 Warnings and Precautions, Hematologic)	Grade 3	BVd/BPd	<p>No bleeding:</p> <ul style="list-style-type: none"> For patients on 2.5 mg/kg, reduce BLENREP to 1.9 mg/kg. For patients on 1.9 mg/kg or lower, continue BLENREP at same dose. <p>With bleeding:</p> <ul style="list-style-type: none"> Withhold BLENREP until improvement to Grade 2 or better. For patients previously on 2.5 mg/kg, resume BLENREP at 1.9 mg/kg. For patients on 1.9 mg/kg or lower, resume BLENREP at same dose. <p>Consider additional supportive treatment (e.g., transfusion), as clinically indicated and per local practice.</p>
	Grade 4	BVd/BPd	<p>Withhold BLENREP and consider restarting if recovered to Grade 3 or better, and only if there is no active bleeding at time of restart.</p> <p>For patients previously on 2.5 mg/kg, resume BLENREP at 1.9 mg/kg.</p> <p>For patients on 1.9 mg/kg or lower, resume BLENREP at same dose.</p> <ul style="list-style-type: none"> If thrombocytopenia is considered disease-related, is not accompanied by bleeding, and recovers with transfusion to $>25 \times 10^9/L$, continuation of the current dose of BLENREP may be

			considered.
Infusion-related reactions (see 7 Warnings and Precautions, Immune)	Grade 2	BVd/BPd	Interrupt infusion and provide supportive care. Once symptoms resolve to Grade 1 or better, consider premedication and resume BLENREP at a decreased infusion rate by at least 50%.
	Grade 3	BVd/BPd	Interrupt infusion and provide supportive care. Once symptoms resolve to Grade 1 or better, resume with premedication and at lower infusion rate extended to 2 to 4 hours. Any future infusion requires premedication.
	Grade 4	BVd/BPd	Permanently discontinue BLENREP. <ul style="list-style-type: none"> If anaphylactic or life-threatening infusion reaction, permanently discontinue the infusion and institute appropriate emergency care.
Other adverse reactions (see 8 Adverse Reactions)	Grade 3	BVd/BPd	Withhold BLENREP until improvement to Grade 1 or better. For patients previously on 2.5 mg/kg, resume BLENREP at 1.9 mg/kg. For patients on 1.9 mg/kg or lower, resume BLENREP at same dose.

	Grade 4	BVd/BPd	<p>Consider permanent discontinuation of BLENREP.</p> <p>If continuing treatment, withhold BLENREP until improvement to Grade 1 or better.</p> <p>For patients previously on 2.5 mg/kg, resume BLENREP at 1.9 mg/kg.</p> <p>For patients on 1.9 mg/kg or lower, resume BLENREP at same dose.</p>
--	---------	---------	--

BCVA = best corrected visual acuity

- ^a Non-ocular adverse reaction grading is according to the National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).
- ^b Pomalidomide and dexamethasone may be continued during BLENREP dose holds, if warranted, per the judgement of the treating physician.
- ^c Ocular adverse reaction severity is defined by the most severely affected eye as both eyes may not be affected to the same degree.
- ^d If toxicity is identified prior to dosing cycle 2 for BPd, dose at 1.9 mg/kg every 4 weeks.
- ^e A corneal defect may lead to corneal ulcers. These should be managed promptly and as clinically indicated by an eye care professional.

4.3. Reconstitution

BLENREP is a cytotoxic anticancer medicinal product. Follow applicable special handling and disposal procedures. Use aseptic technique for the reconstitution and dilution of the dosing solution.

Calculate the dose (mg), total volume (mL) of solution required and the number of vials of BLENREP needed based on the patient's actual body weight (kg). More than 1 vial may be needed for a full dose. Do not round down for partial vials.

Reconstitution Instructions (Reconstituted Solution)

1. Remove the vial(s) of BLENREP from the refrigerator and allow to stand for approximately 10 minutes to reach room temperature (20°C to 25°C).
2. Reconstitute each 70 mg vial of BLENREP with 1.4 mL of Sterile Water for Injection to obtain a final concentration of 50 mg/mL. Reconstitute each 100 mg vial with 2 mL of Sterile Water for Injection to obtain a final concentration of 50 mg/mL. Gently swirl the vial to aid dissolution. **Do not shake.**
3. If the reconstituted solution is not used immediately, store refrigerated at 2°C to 8°C or at room temperature (20°C to 25°C) for up to 4 hours in the original container. Discard if not diluted within 4 hours. **Do not freeze.**
4. Visually inspect the reconstituted solution for particulate matter and discoloration. The reconstituted solution should be a clear to opalescent, colourless to yellow to brown liquid.

Discard the reconstituted vial if extraneous particulate matter other than translucent to white proteinaceous particles is observed (see [11 Storage, Stability and Disposal](#)).

Dilution Instructions for Intravenous Use (Diluted Solution)

1. Withdraw the necessary volume of BLENREP for the calculated dose from each vial.
2. Add the necessary amount of BLENREP into the infusion bag containing 250 mL of sodium chloride 9 mg/mL (0.9%) solution for injection. Mix the diluted solution by gentle inversion. The final concentration of the diluted solution should be between 0.2 mg/mL to 2 mg/mL. **Do not shake.**
3. The diluted infusion solution should be clear and colorless. Discard if particulate matter is observed.
4. If not used immediately, the diluted solution may be stored in a refrigerator (2°C to 8°C) for up to 24 hours prior to administration. Diluted infusion solution may be kept at room temperature for no more than 6 hours (including infusion time). **Do not freeze.**
5. Discard any unused reconstituted solution of BLENREP left in the vial(s) (see [11 Storage, Stability and Disposal](#)).

4.4. Administration

1. If the diluted solution is refrigerated, allow the diluted solution to equilibrate to room temperature (20°C to 25°C) prior to administration.
2. Administer BLENREP by intravenous infusion over approximately 30 minutes using an infusion set made of polyvinyl chloride (PVC) or polyolefin (PO).
3. Filtration of the diluted solution is not required. However, if the diluted solution is filtered, use a polyethersulfone (PES) based filter (0.2 micron).

5. Overdose

Symptoms and signs

There has been no experience of overdosage with BLENREP in clinical studies. Doses of up to 4.6 mg/kg every 3 weeks have been administered in clinical studies.

Treatment

There is no known specific antidote for overdose with BLENREP. In the event of an overdose, the patient should be monitored for any signs or symptoms of adverse effects and appropriate supportive treatment should be instituted immediately.

For the most recent information in the management of a suspected drug overdose, contact your regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669).

6. Dosage Forms, Strengths, Composition, and Packaging

To help ensure the traceability of biologic products health professionals should record the brand name, the non-proprietary (active ingredient) name, and other product-specific identifiers such as the Drug Identification Number (DIN) and the batch/lot number of the product supplied.

Table 5 Dosage Forms, Strengths, and Composition

Route of Administration	Dosage Form / Strength / Composition	Non-Medicinal Ingredients
Intravenous infusion	Dosage form: Powder for solution for infusion Active ingredient: Belantamab mafodotin Strengths: 70 mg/vial or 100 mg/vial	Citric acid monohydrate; disodium edetate dihydrate; polysorbate 80; trehalose dihydrate; trisodium citrate dihydrate; water for injection.

Packaging

BLENREP is presented as a sterile lyophilized white to yellow powder in a single-use vial with bromobutyl rubber stopper and a blue removable cap for 70 mg and orange removable cap for 100 mg.

BLENREP is supplied in a single use vial without a preservative. The vials contain 70 mg or 100 mg of belantamab mafodotin. After reconstitution, the solution contains 70 mg per 1.4 mL or 100 mg per 2 mL (50 mg per mL) of belantamab mafodotin.

7. Warnings and Precautions**General**

BLENREP is administered in combination with bortezomib and dexamethasone, or pomalidomide and dexamethasone. The Product Monographs of the medications, used in combination with BLENREP, should be consulted before starting treatment.

Driving and Operating Machinery

BLENREP may impair one’s ability to drive and use machines. Due to the potential for BLENREP to affect the eyes, patients experiencing vision changes should be advised to refrain from driving or operating machinery until evaluated by an eyecare professional and thereafter, to adhere to the eyecare professional’s recommendations.

Hematologic

- Thrombocytopenia**

Thrombocytopenia (thrombocytopenia and platelet count decreased) was very common in patients who were administered BLENREP as a part of combination regimens. Thrombocytopenia may lead to serious bleeding, including gastrointestinal and intracranial bleeding.

Complete blood counts should be obtained at baseline and monitored during treatment, as clinically indicated. Patients experiencing Grade 3 or 4 thrombocytopenia or those on concomitant anticoagulant treatments may require more frequent monitoring and should be managed with a dose modification depending on the severity (see [4.2 Recommended Dose and Dosage Adjustment](#)). Supportive therapy (e.g. platelet transfusions) should be provided according to standard medical practice.

Immune

- **Infections**

BLENREP, in combination with bortezomib and dexamethasone or pomalidomide and dexamethasone, may increase the risk of infection. In both clinical trials, the incidence of pneumonia was higher in patients who received BVd compared to DVd, or BPd compared to PVd. Monitor patients for signs and symptoms of infection prior to and during treatment with BLENREP and treat appropriately (see [4.2 Recommended Dose and Dosage Adjustment](#)). Consider prophylactic antimicrobials in accordance with current practice guidelines.

- **Infusion Reactions**

Infusion-related reactions (IRR) have been reported with BLENREP. Most IRRs were Grade 1 or 2 and resolved within the same day (see [8.2 Clinical Trial Adverse Reactions, Infusion-Related Reactions](#)). If a Grade 2 or higher IRR occurs during administration, reduce the infusion rate or stop the infusion depending on the severity of the symptoms. Institute appropriate medical treatment and restart infusion at a slower rate, if the patient's condition is stable. If Grade 2 or higher IRR occurs, administer premedication for subsequent infusions (see [4.2 Recommended Dose and Dosage Adjustment](#)).

Ophthalmologic

BLENREP frequently causes ocular adverse reactions, resulting in ocular symptoms including blurred vision, dry eye, eye irritation, and photophobia.

Adverse corneal events and worsening of visual acuity were both very common in patients treated with BLENREP during clinical trials. Some patients experienced severe corneal events (e.g., corneal ulcers) and/or worsening of visual acuity (e.g., Snellen visual acuity worse than 20/200) (see [8.2 Clinical Trial Adverse Reactions](#)). The most commonly reported corneal examination findings include superficial punctate keratopathy, microcyst-like epithelial changes, stippled vortex staining pattern, sub-epithelial haze, corneal epithelial defects and stromal opacity with or without changes in visual acuity. Clinically relevant changes in visual acuity may be associated with difficulty in driving or operating machinery and affected patients should be advised to refrain from driving or operating machinery.

Ophthalmic examinations, including assessment of visual acuity and slit lamp examination, should be performed before each dose of BLENREP or more frequently as clinically indicated. If changes in vision or corneal signs are not observed at or before the sixth dose, ophthalmic exam frequency may be reduced to approximately every 3 months, and whenever clinically indicated. Patients should be advised to report ocular symptoms to their health care professional promptly.

Patients should be advised to administer preservative-free artificial tears at least 4 times a day during treatment (see [4.1 Dosing Considerations](#)). Patients should avoid using contact lenses until they are no longer receiving BLENREP. Bandage contact lenses may be used under the direction of an ophthalmologist.

Corneal examination findings (e.g., keratopathies such as superficial punctate keratopathy or microcyst-like deposits) with or without changes in visual acuity may require a dose modification (delay and/or reduction) or treatment discontinuation based on severity of findings (see [4.2 Recommended Dose and Dosage Adjustment](#)). Changes in visual acuity observed with or without corneal findings may require dose delays and/or reductions (see [4.2 Recommended Dose and Dose Adjustment](#)). In clinical trials, most patients who received BLENREP required dose delays or reductions due to ocular adverse reactions, corneal examination findings and/or worsening visual acuity.

Cases of corneal ulcer (ulcerative and infective keratitis) have been reported (see [8.2 Clinical Trial Adverse Reactions](#)). These should be managed promptly and as clinically indicated by an eye care professional. Treatment with BLENREP should be withheld until the corneal ulcer has healed or permanently discontinued if unresponsive to appropriate management (see [4.2 Recommended Dose and Dosage Adjustment](#)).

Additional information on ocular adverse reactions and their management is available in educational materials for patients and prescribers. These educational materials are available upon request by contacting GSK Medical Information at 1-800-387-7374.

Reproductive Health

- **Fertility**

Based on findings in animals and the mechanism of action, BLENREP may impair fertility in females and males of reproductive potential (see [16 Non-Clinical Toxicology](#)). Pregnancy testing is recommended for females of reproductive potential prior to initiating BLENREP.

- **Women of child-bearing potential/Contraception**

Females: The pregnancy status of child-bearing women should be verified prior to initiating therapy with BLENREP. Advise women of child-bearing potential to inform their healthcare provider of a known or suspected pregnancy, and to use effective contraception during treatment with BLENREP and for 4 months after the last dose.

Males: Advise males with female partners of childbearing potential to use effective contraception during treatment with BLENREP and for 6 months after the last dose.

Respiratory

- **Pneumonitis**

Cases of pneumonitis, including fatal events, have been observed with BLENREP although a causal association has not been established. Evaluation of patients with new or worsening unexplained pulmonary symptoms (e.g. cough, dyspnea) should be performed to exclude possible pneumonitis. In case of suspected Grade 3 or higher pneumonitis, BLENREP should be withheld. If Grade 3 or higher pneumonitis is confirmed, initiate appropriate treatment. BLENREP should only be resumed after an evaluation of the benefit and risk.

7.1. Special Populations

7.1.1. Pregnancy

There is no data on the use of BLENREP in pregnant women. Based on the mechanism of action of the cytotoxic component monomethyl auristatin F (MMAF) that actively targets dividing cells, BLENREP can cause embryo-fetal harm when administered to a pregnant woman (see [16 Nonclinical Toxicology](#)). Human immunoglobulin G (IgG) is known to cross the placenta; therefore, BLENREP has the potential to be transmitted from the mother to the developing fetus.

BLENREP should not be used during pregnancy unless the benefit to the mother outweighs the potential risk to the fetus. If a pregnant woman needs to be treated, she should be clearly advised on the potential risk to the fetus.

7.1.2. Breastfeeding

It is not known whether BLENREP is excreted into human milk. Immunoglobulin G (IgG) is present in human milk in small amounts. Since BLENREP is a humanised IgG monoclonal antibody, and based on the mechanism of action, it may cause serious adverse reactions in breastfed children. Women should be advised to discontinue breast-feeding prior to initiating treatment with BLENREP, and for 3 months after the last dose.

7.1.3. Pediatrics

Pediatrics (<18 years of age): The safety and efficacy of BLENREP in children and adolescents less than 18 years of age have not been studied; therefore, BLENREP is not indicated for pediatric use.

7.1.4. Geriatrics

Geriatrics (≥ 65 years of age): No overall differences in safety or efficacy were observed between older patients (65 years and over) and younger patients (less than 65 years).

8. Adverse Reactions

8.1. Adverse Reaction Overview

The safety profile of BLENREP in combination with bortezomib and dexamethasone was studied in an open label Phase I/II study (DREAMM-6) and a Phase III trial (DREAMM-7). The information provided in this section, pertaining to the safety of BLENREP when used in combination with bortezomib and dexamethasone, is based on the pivotal DREAMM-7 study.

The safety profile of BLENREP in combination with pomalidomide and dexamethasone was studied in an open label Phase II study (Algonquin) and in a pivotal Phase III trial (DREAMM-8). The information provided in this section pertaining to the safety of BLENREP when used in combination with pomalidomide and dexamethasone is based on the pivotal DREAMM-8 study.

Combination therapy with bortezomib and dexamethasone

DREAMM-7: The safety of BLENREP in combination with bortezomib and dexamethasone was evaluated in 242 patients in DREAMM-7, a randomized, open-label, Phase III, multicentre study which compared the combination therapy with daratumumab, bortezomib and dexamethasone in patients with multiple myeloma who have received at least one prior therapy.

Adverse reactions, excluding ophthalmic examination findings, leading to permanent discontinuation of any component of therapy occurred in 32% of patients. Permanent discontinuation due to ocular events including ocular adverse reactions, visual acuity changes or corneal examination findings occurred in 10% of patients. Adverse reactions, excluding ophthalmic examination findings, leading to dose delay of any component of therapy occurred in 95% of patients and in 78% of patients with ocular events. Adverse reactions, excluding ophthalmic examination findings, leading to dose reduction of any component of therapy occurred in 75% of patients and in 43% of patients with ocular events.

Combination therapy with pomalidomide and dexamethasone

DREAMM-8: The safety of BLENREP in combination with pomalidomide and dexamethasone was evaluated in 150 patients in DREAMM-8, a randomized, open-label, Phase III, multi-centre study which

compared the combination therapy with pomalidomide, bortezomib and dexamethasone in patients with multiple myeloma who have received at least one prior therapy, including lenalidomide.

Adverse reactions, excluding ophthalmic examination findings, leading to permanent discontinuation of any component of therapy occurred in 19% of patients, and permanent discontinuation due to ocular events, including ocular adverse reactions, visual acuity changes, or corneal examination findings were 11%. Adverse reactions, excluding ophthalmic examination findings, leading to dose delay of any component of therapy occurred in 91% of patients and in 83% of patients due to ocular events. Adverse reactions, excluding ophthalmic examination findings, leading to dose reduction of any component of therapy occurred in 63% of patients, and in 59% of patients due to ocular events.

8.2. Clinical Trial Adverse Reactions

Clinical trials are conducted under very specific conditions. Therefore, the frequencies of adverse reactions observed in the clinical trials may not reflect frequencies observed in clinical practice and should not be compared to frequencies reported in clinical trials of another drug.

Combination therapy with bortezomib and dexamethasone (DREAMM-7)

The safety of BLENREP was evaluated in DREAMM-7 in 242 patients who received BLENREP in combination with bortezomib and dexamethasone and compared to 246 patients who received a regimen consisting of daratumumab, bortezomib and dexamethasone.

The most common adverse reactions (occurring in $\geq 20\%$ of patients) were pneumonia, alanine aminotransferase increased, fatigue, reduced visual acuity (BCVA), thrombocytopenia, corneal examination findings, blurred vision, dry eye, photophobia, foreign body sensation in eyes, eye irritation, diarrhea, eye pain, peripheral sensory neuropathy, cataract and upper respiratory tract infection. The most common Grade 3 or 4 ($\geq 5\%$) laboratory abnormalities were anemia, white blood cell decreased, lymphocyte count decreased, neutrophil count decreased, platelet count decreased, alanine aminotransferase increased, aspartate aminotransferase increased, and gamma-glutamyl transferase increased.

Adverse reactions leading to dose delays of any component of therapy occurred in 95% (n=229) of patients. Dose delays of any component of therapy due to ocular adverse events occurred in 78% of patients. Adverse reactions excluding ocular events, that led to a dose delay in $>3\%$ of patients included thrombocytopenia (35%), platelet count decreased (12%), upper respiratory tract infection (13%), pneumonia (17%), diarrhea (8%), pyrexia (7%), and neutropenia (6%), and alanine aminotransferase increased (4%).

Adverse reactions leading to dose reductions of any component of therapy occurred in 75% (n=181) of patients. Ocular adverse reactions led to dose reductions in 44% of patients. Adverse reactions excluding ocular events, that led to a dose reduction in $\geq 2\%$ of patients included thrombocytopenia (29%), platelet count decreased (9%), and fatigue (3%).

Serious adverse reactions occurred in 53% (n=129) of patients who received BLENREP. Serious adverse reactions that occurred in $\geq 2\%$ of patients included pneumonia (17%), pyrexia (5%), thrombocytopenia (3%), and anemia (2%). Fatal adverse reactions occurred in 11% of patients. Adverse reactions leading to death in at least 1% of patients (i.e., ≥ 3 patients) who received BLENREP were pneumonia (4%).

Permanent discontinuation of BLENREP due to any adverse reaction occurred in 21% of patients. The most common adverse reactions ($>3\%$) leading to permanent discontinuation of any component of BVD were ocular events (10%) and pneumonia (5%).

Table 6 summarizes the adverse reactions in DREAMM-7 for patients who received BLENREP 2.5 mg/kg once every 3 weeks with bortezomib and dexamethasone compared to daratumumab with bortezomib and dexamethasone.

Table 6 Adverse Reactions (≥10%) in Patients who Received BLENREP in DREAMM-7

Adverse Reactions	BLENREP + bortezomib and dexamethasone (BVd) n = 242		Daratumumab + bortezomib and dexamethasone (DVd) n = 246	
	All Grades n (%)	Grade 3+4 n (%)	All Grades n (%)	Grade 3+4 n (%)
Eye disorders				
Reduced visual acuity (BCVA) ^a	217 (90)	143 (59)	115 (47)	17 (7)
Corneal examination findings (including keratopathy) ^a	218 (90)	188 (78)	62 (25%)	8 (3)
Blurred vision	165 (68)	58 (24)	27 (11)	3 (1)
Dry eye	129 (53)	17 (7)	19 (8)	0
Photophobia	120 (50)	7 (3)	6 (2)	0
Foreign body sensation in eyes	111 (46)	9 (4)	12 (5)	0
Eye irritation	110 (45)	12 (5)	14 (6)	0
Eye pain	81 (33)	2 (<1)	9 (4)	1 (<1)
Visual impairment	26 (11)	12 (5)	4 (2)	1 (<1)
Lacrimation increased	24 (10)	2 (<1)	8 (3)	0
Blood and lymphatic system disorders				
Thrombocytopenia ^b	212 (88)	176 (73)	160 (65)	113 (46)
Anemia ^e	53 (22)	21 (9)	66 (27)	25 (10)
Neutropenia ^c	45 (19)	34 (14)	44 (18)	24 (10)
Lymphopenia ^d	33 (14)	20 (8)	36 (15)	27 (11)
Leukopenia ^e	27 (11)	11 (5)	22 (9)	11 (4)
Gastrointestinal disorders				
Diarrhea	80 (33)	10 (4)	78 (32)	10 (4)
Nausea	39 (16)	2 (<1)	31 (13)	0
Infections and infestations				
Upper respiratory tract infection	54 (22)	1 (<1)	54 (22)	0

Adverse Reactions	BLENREP + bortezomib and dexamethasone (BVd) n = 242		Daratumumab + bortezomib and dexamethasone (DVd) n = 246	
	All Grades n (%)	Grade 3+4 n (%)	All Grades n (%)	Grade 3+4 n (%)
Pneumonia ^f	61 (25)	30 (12)	35 (14)	13 (5)
General disorders and administration site conditions				
Pyrexia	47 (19)	1 (<1)	25 (10)	3 (1)
Fatigue ^h	68 (28)	14 (6)	71 (29)	9 (4)
Investigations				
Alanine aminotransferase increased	48 (20)	14 (6)	30 (12)	4 (2)
Aspartate aminotransferase increased	37 (15)	4 (2)	13 (5)	0
Gamma glutamyl transferase increased	39 (16)	24 (10)	11 (4)	4 (2)

BCVA = best corrected visual acuity.

Non-ophthalmic examination findings toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).

^a Based on ophthalmic examination findings.

^b Thrombocytopenia included thrombocytopenia and platelets decreased.

^c Neutropenia included neutropenia, neutrophil count decreased, and febrile neutropenia.

^d Lymphopenia included lymphopenia and lymphocyte count decreased.

^e Leukopenia included leukopenia and white blood cell count decreased.

^f Based on the MedDRA SMQ Infective pneumonia (narrow)

^g Anemia included anemia, hemoglobin decreased, iron deficiency anemia, macrocytic anemia, and red blood cell decreased.

^h Fatigue included fatigue, asthenia, and malaise

Description of Select Adverse Reactions in DREAMM-7

Ocular Adverse Reactions

The most common adverse reactions (>25%) included reduced visual acuity (90%; 59% Grades 3 and 4) and corneal examination findings (90%; 78% Grades 3 and 4) based on the ophthalmic examination findings, blurred vision (68%; 24% Grades 3 and 4), dry eye (53%; 8% Grades 3 and 4), photophobia (50%; 3% Grades 3 and 4), foreign body sensation in eyes (46%; 4% Grades 3 and 4), eye irritation (45%; 5% Grades 3 and 4) and eye pain (33%; <1% Grades 3 and 4) based on CTCAE grading. Patients who experienced a CTCAE graded ocular adverse reaction had a median of 1 event per patient.

Corneal examination findings (keratopathies such as superficial punctate keratopathy and microcyst-like deposits) were reported based on the ophthalmic examination findings as Grade 1 in 4% of patients, Grade 2 in 9%, Grade 3 in 57%, and Grade 4 in 20%. Cases of corneal ulcer (ulcerative and infective keratitis) were reported with an incidence of <1% (n = 2).

There were 88% (212/242) of patients with at least 1 corneal examination finding or BCVA-related event (Grade ≥ 2) in the BVd arm with a median of 3 events per patient. Among patients who experienced an event, 91% (190/209) continued treatment on or after the onset of the first event managed by dose reduction or delay and received a median of 8 additional doses (range: 1 to 52).

Table 7 includes a summary of ocular adverse reactions, decreased vision in patients with normal (Snellen equivalent visual acuity 20/25 or better in at least one eye) baseline, and corneal examination findings in DREAMM-7. Upon resumption of BLENREP, ocular adverse events may recur. In DREAMM-7 a total of 724 KVA scale events (Grade 2 or higher) were reported with a median time to resolution to Grade 1 or better of 85 days (range 5 to 813).

Table 7 Summary of BLENREP associated ocular adverse reactions in DREAMM-7

	Ocular adverse reactions ^a	Best Corrected Visual Acuity (BCVA) ^{b,c}		Corneal examination findings (Grade 2+ events) ^d
		20/50 or worse	20/200 or worse	
Number of patients with event, n (%)	194 (80)	84 (35)	5 (2)	209 (86)
Median number of events per patient (range)	1 (1, 14)	2 (1, 9)	1 (1, 1)	3 (1, 16)
First event				
Median time to first event, (days)	42	79	105	43
Resolution of first event, n (%) ^{c,e}	88 (45)	78 (93)	4 (80)	180 (86)
Median time to resolution of first event (days)	51	63.5	86.5	106
Ongoing first event, n (%) ^e	106 (55)	6 (7)	1 (20)	29 (14)
Treatment ongoing, n (%)	28 (14)	1 (1)	-	-
Discontinued treatment and follow-up ongoing, n (%)	40 (21)	-	-	5 (2)
Discontinued treatment and follow-up ended, n (%)	38 (20)	5 (6)	1 (20)	24 (11)
Outcome of Any Event^e				
Total Number of Events, n	569	173	5	935
Number of Events Resolved, n (%)	480 (84)	158 (91)	4 (80)	843 (90)

^a Resolution of ocular adverse reactions was defined as being free from any ocular adverse reactions.

^b Events reflect bi-lateral worsening of BCVA.

^c Resolution of visual acuity was defined as 20/25 or better in at least one eye.

^d Resolution of corneal examination findings was defined as Grade 1 or better based on the ophthalmic examination findings.

^e At the time of data cut off (07 OCT 2024)

Infusion-Related Reactions

In the DREAMM-7 study, the incidence of infusion-related reactions (IRR) was 2% (n = 5). All IRRs were reported as Grade 1 (<1%) and Grade 2 (1%).

Thrombocytopenia

In the DREAMM-7 study, thrombocytopenic events (thrombocytopenia and platelet count decreased) occurred in 88% of patients (n = 212). Grade 2 thrombocytopenic events occurred in 10% of patients, Grade 3 in 26%, and Grade 4 in 47%. Clinically significant bleeding (Grade ≥ 2) occurred in 7% of patients with concomitant low platelet levels (Grades 3 to 4).

Infections

In the DREAMM-7 study, pneumonia was reported in 25% (n=61) of patients with 17% reported as Grade ≥ 3 . There were nine (9) patients who had a pneumonia event with worst outcome listed as fatal.

Combination therapy with pomalidomide and dexamethasone (DREAMM-8)

DREAMM-8: The safety of BLENREP was evaluated in DREAMM-8, a randomized, open-label, Phase III, multi-centre study in combination with pomalidomide and dexamethasone in 150 patients compared to 145 patients who received bortezomib in combination with pomalidomide and dexamethasone.

The most common adverse reactions (occurring in $\geq 20\%$ of patients) were reduced visual acuity (BCVA; 91%), corneal examination findings (89%), blurred vision (80%), neutropenia (65%), foreign body sensation in eyes (61%), dry eye (61%), thrombocytopenia (54%), eye irritation (51%), photophobia (46%), fatigue (40%), pneumonia (39%), eye pain (33%), upper respiratory tract infections (28%), anemia (25%), and diarrhea (25%). The most common Grade 3 or 4 ($\geq 5\%$) laboratory abnormalities were neutrophil count decreased, lymphocyte count decreased, platelet count decreased, white blood cell decreased, and anemia.

Adverse reactions leading to dose delays of any component of therapy occurred in 95% (n=143) of patients receiving BLENREP in combination with pomalidomide and dexamethasone. Dose delays of any component of therapy due to ocular adverse events occurred in 83% of patients. Adverse reactions excluding ocular events that led to a dose delay in $>3\%$ of patients included pneumonia (31%), neutropenia (24%), upper respiratory tract infection (17%), neutrophil count decreased (10%), pyrexia (8%), platelet count decreased (7%), fatigue (7%), thrombocytopenia (5%), anemia (5%), diarrhea (5%), and alanine aminotransferase increased (4%).

Adverse reactions leading to dose reductions of any component of therapy occurred in 78% (n=117) of patients. Ocular adverse reactions led to dose reductions in 59% of patients. Adverse reactions excluding ocular events, that led to a dose reduction in $\geq 2\%$ of patients included neutropenia (16%), neutrophil count decreased (10%), fatigue (7%), platelet count decreased (4%), thrombocytopenia (4%), and pneumonia (2%).

Serious adverse reactions occurred in 67% (n=101) of patients who received BLENREP. Serious adverse reactions that occurred in $\geq 2\%$ of patients included pneumonia (31%), neutropenia (7%), and upper respiratory tract infection (2%). Fatal adverse reactions occurred in 13% of patients, which included pneumonia in 5% of patients. Permanent discontinuation of BLENREP due to any adverse reaction occurred in 19% of patients. Ocular adverse reactions were the most common reason for permanent discontinuation of any component of BPd (11%).

Table 8 summarizes the adverse reactions in DREAMM-8 for patients who received BLENREP 2.5 mg/kg once followed by 1.9 mg/kg once every 4 weeks with pomalidomide and dexamethasone compared to

pomalidomide with bortezomib and dexamethasone.

Table 8 Adverse Reactions (≥10%) in Patients Who Received BLENREP in DREAMM-8

Adverse Reactions	BLENREP + pomalidomide and dexamethasone (BPd) n = 150		Pomalidomide + bortezomib and dexamethasone (PVd) n = 145	
	All Grades n (%)	Grade 3-4 n (%)	All Grades n (%)	Grade 3-4 n (%)
Eye disorders				
Reduced visual acuity (BCVA) ^a	137 (91)	91 (61)	52 (36)	11 (8)
Corneal examination findings (including keratopathy) ^a	134 (89)	99 (66)	33 (23)	1 (<1)
Blurred vision	120 (80)	26 (17)	23 (16)	0
Dry eye	92 (61)	13 (9)	14 (10)	0
Foreign body sensation in eyes	91 (61)	9 (6)	11 (8)	0
Eye irritation	77 (51)	6 (4)	14 (10)	0
Photophobia	69 (46)	5 (3)	6 (4)	0
Eye pain	49 (33)	3 (2)	8 (6)	0
Visual impairment	23 (15)	15 (10)	2 (1)	1 (<1)
Blood and lymphatic disorders				
Neutropenia ^b	97 (65)	87 (58)	69 (48)	60 (41)
Thrombocytopenia ^c	81 (54)	57 (38)	60 (41)	42 (29)
Anemia ^d	37 (25)	16 (11)	44 (30)	21 (14)
Leukopenia ^e	15 (10)	9 (6)	12 (8)	6 (4)
Infections and infestations				
Upper respiratory tract infection	42 (28)	3 (2)	26 (18)	1 (<1)
Pneumonia ^f	59 (39)	42 (28)	26 (18)	16 (11)
General disorders and administration site conditions				
Fatigue ^g	60 (40)	12 (8)	52 (36)	13 (9)
Pyrexia	29 (19)	1 (<1)	11 (8)	2 (1)
Gastrointestinal disorders				
Diarrhea	37 (25)	2 (1)	34 (23)	12 (8)
Nausea	20 (13)	1 (<1)	16 (11)	0

Adverse Reactions	BLENREP + pomalidomide and dexamethasone (BPd) n = 150		Pomalidomide + bortezomib and dexamethasone (PVd) n = 145	
	All Grades n (%)	Grade 3-4 n (%)	All Grades n (%)	Grade 3-4 n (%)
Investigations				
Alanine aminotransferase increased	25 (17)	3 (2)	13 (9)	5 (3)
Aspartate aminotransferase increased	17 (11)	5 (3)	11 (8)	3 (2)

BCVA = best corrected visual acuity.

Non-ophthalmic examination findings toxicity was graded per National Cancer Institute Common Terminology Criteria for Adverse Events (CTCAE).

- a Based on ophthalmic examination findings.
- b Neutropenia included neutropenia, neutrophil count decreased, and febrile neutropenia.
- c Thrombocytopenia included thrombocytopenia and platelet count decreased.
- d Anemia included anaemia, anaemia macrocytic, iron deficiency anaemia, haemoglobin decreased, red blood cell count decreased
- e Leukopenia included leukopenia and white blood cell count decreased
- f Based on MedDRA SMQ infective pneumonia (narrow)
- g Fatigue included fatigue, asthenia, malaise

Description of Select Adverse Reactions in DREAMM-8

Ocular Adverse Reactions

The most common adverse reactions (>25%) included reduced visual acuity (91%; 61% Grade 3 and 4) and corneal examination findings (89%; 66% Grade 3 and 4) based on the ophthalmic examination findings, blurred vision (80%; 17% Grade 3 and 4), dry eye (61%; 9% Grade 3 and 4), foreign body sensation in eyes (61%; 6% Grade 3 and 4), eye irritation (51%; 4% Grade 3 and 4), photophobia (46%; 3% Grade 3 and 4), and eye pain (33%; 2% Grade 3 and 4) based on CTCAE grading. Patients who experienced a CTCAE grade ocular adverse reaction had a median of 2 events per patient.

Corneal examination findings (keratopathies such as superficial punctate keratopathy and microcyst-like deposits) were reported based on the ophthalmic examination findings as Grade 1 in 6% of patients, Grade 2 in 17%, Grade 3 in 56%, and Grade 4 in 10%. Cases of corneal ulcer (ulcerative keratitis) were reported with an incidence of 2% (n = 3).

There were 89% (133/150) of patients with at least 1 corneal examination finding or BCVA-related event (Grade ≥2) in the BPd arm with a median of 3 events per patient. Among patients who experienced an event, 92% (120/131) continued treatment on or after the onset of the first event managed by dose reduction or delay and received a median of 5 additional doses (range: 1 to 21).

Table 9 includes a summary of ocular adverse reactions, decreased vision in patients with normal (Snellen equivalent visual acuity 20/25 or better in at least one eye) baseline, and corneal examination findings in DREAMM-8. Upon resumption of BLENREP, ocular adverse events can recur. In DREAMM-8 a

total of 441 KVA scale events (Grade 2 or higher) were reported with a median time to resolution to Grade 1 or better of 85 days (range 15 to 746).

Table 9 Summary of BLENREP associated ocular adverse events in DREAMM-8

	Ocular adverse reactions ^a	Best Corrected Visual Acuity (BCVA) ^{b,c}		Corneal examination findings (Grade 2+ events) ^d
		20/50 or worse for patients	20/200 or worse for patients	
Number of patients with event, n (%)	133 (89)	51 (34)	2 (1)	125 (83)
Median number of events per patient (range)	2 (1, 11)	1 (1, 5)	1 (1, 1)	1 (1, 13)
First event				
Median time to first event, days	29	112	NA ^e	29
Resolution of first event ^{c,f} , n (%)	109 (82)	45 (88)	1 (50)	113 (90)
Median time to resolution of first event (days)	134.5	57	NA ^e	88
Ongoing first event ^f , n (%)	24 (18)	6 (12)	1 (50)	12 (10)
Treatment ongoing, n (%)	5 (4)	1 (2)	0	0
Discontinued treatment and follow-up ongoing, n (%)	6 (5)	1 (2)	0	4 (3)
Discontinued treatment and follow-up ended, n (%)	13 (10)	4 (8)	1 (50)	8 (6)
Outcome of Any Event^f				
Total Number of Events, n	376	87	2	490
Number of Events Resolved, n (%)	317 (84)	76 (87)	1 (50)	448 (91)

^a Resolution of ocular adverse reactions was defined as being free from any ocular adverse reactions.

^b Events reflect bi-lateral worsening of BCVA.

^c Resolution of visual acuity was defined as 20/25 or better in at least one eye.

^d Resolution of corneal examination findings was defined as Grade 1 or better based on the ophthalmic examination findings.

^e In patients with 20/200 or worse, two patients were reported. Time to first onset was 29 and 673 days. Both events improved to better than bilateral 20/200 by the data cut-off, of which 1 event resolved to baseline in 57 days.

^f At the time of the data cut-off (07 OCT 2024).

Infusion Related Reactions

In the DREAMM-8 study, the incidence of IRR was 7% (n = 11). Most IRRs were reported as Grade 1 (1%) and Grade 2 (5%) while 1% experienced Grade 3 IRRs. One patient discontinued treatment due to IRRs.

Thrombocytopenia

In the DREAMM-8 study, thrombocytopenic events (thrombocytopenia and platelet count decreased) occurred in 54% of patients (n = 81). Grade 2 thrombocytopenic events occurred in 11% of patients, Grade 3 in 26%, and Grade 4 in 12%. Clinically significant bleeding (\geq Grade 2) with concomitant low platelet levels (Grades 3 to 4) occurred in 3% of patients.

Infections

In the DREAMM-8 study, pneumonia was reported in 39% (n=59) of patients with 32% reported as Grade \geq 3. There were seven (7) patients who had a pneumonia event with a fatal outcome.

8.3. Less Common Clinical Trial Adverse Reactions in <10% of patients

Combination therapy with bortezomib and dexamethasone (DREAMM-7)

Eye Disorders: Diplopia, eye pruritus, ocular discomfort, corneal ulcer.

Gastrointestinal Disorders: Vomiting.

Hepatobiliary Disorders: Porto-sinusoidal vascular disorder

Injury, poisoning, and procedural complications: Infusion-related reactions.

Investigations: Creatine phosphokinase increased.

Renal and Urinary Disorders: Albuminuria.

Combination therapy with pomalidomide and dexamethasone (DREAMM-8)

Blood Disorders: Lymphopenia.

Eye Disorders: Lacrimation increased, diplopia, eye pruritus, corneal ulcers, ocular discomfort.

Gastrointestinal Disorders: Vomiting.

Hepatobiliary Disorders: Porto-sinusoidal vascular disorder.

Injury, poisoning, and procedural complications: Infusion-related reactions.

Investigations: Gamma glutamyl transferase increased, blood creatine phosphokinase increased.

Renal and Urinary Disorders: Albuminuria.

8.4. Abnormal Laboratory Findings: Hematologic, Clinical Chemistry, and Other Quantitative Data

[Table 10](#) summarizes the laboratory abnormalities observed in DREAMM-7. [Table 11](#) summarizes the laboratory abnormalities observed in DREAMM-8.

Table 10 Laboratory Abnormalities Worsening from Baseline in ≥20% Patients who Received BLENREP in DREAMM-7

Laboratory Abnormality	BLENREP + bortezomib and dexamethasone (BVd) n = 242		Daratumumab + bortezomib and dexamethasone (DVd) n = 246	
	All Grades n (%)	Grades 3+4 n (%)	All Grades n (%)	Grades 3+4 n (%)
Hematology				
Anemia	125 (52)	26 (11)	148 (60)	29 (12)
Lymphocyte count decreased	218 (90)	127 (53)	226 (92)	138 (56)
Neutrophil count decreased	127(53)	41 (17)	132 (54)	34 (14)
Platelet count decreased	241 (100)	178 (74)	216 (88)	118 (48)
White blood cell decreased	141 (59)	26 (11)	165 (67)	43 (17)
Chemistry				
Alanine aminotransferase increased	174 (73)	12 (5)	134 (54)	3 (1)
Aspartate aminotransferase increased	211 (88)	13 (5)	100 (41)	0
Gamma glutamyl transferase increased	178 (74)	36 (15)	112 (46)	7 (3)
Creatine kinase increased	116 (49)	8 (3)	77 (32)	7 (3)

Table 11 Laboratory Abnormalities Worsening from Baseline in >20% Patients who Received BLENREP in DREAMM-8

Laboratory Abnormality	BLENREP + pomalidomide and dexamethasone (BPd) n = 150		Pomalidomide + bortezomib and dexamethasone (PVd) n = 145	
	All Grades n (%)	Grades 3+4 n (%)	All Grades n (%)	Grades 3+4 n (%)
Hematology				
Anemia	84 (56)	19 (13)	95 (67)	26 (18)
Lymphocyte count decreased	132 (88)	76 (51)	125 (88)	63 (44)
Neutrophil count decreased	137 (91)	100 (67)	126 (89)	71 (50)
Platelet count decreased	126 (84)	61 (41)	115 (81)	45 (32)
White blood cell decreased	128 (85)	51 (34)	127 (89)	35 (25)
Chemistry				
Alanine aminotransferase increased	88 (59)	5 (3)	62 (44)	5 (4)
Aspartate aminotransferase increased	94 (63)	4 (3)	38 (27)	4 (3)
Gamma glutamyl transferase increased	58 (39)	6 (4)	37 (26)	3 (2)

9. Drug Interactions

9.4. Drug-Drug Interactions

No formal drug interaction studies have been performed with BLENREP.

Effects of BLENREP on the Pharmacokinetics of Other Medicinal Products

In vitro studies demonstrated that cys-mcMMAF is not an inhibitor, an inducer, or a sensitive substrate of cytochrome P450 enzymes, but is a substrate of organic anion transporting polypeptide (OATP)1B1 and OATP1B3, multidrug resistance-associated protein (MRP)1, MRP2, MRP3, bile salt export pump (BSEP), and a possible substrate of P-glycoprotein (P-gp).

Effect of other drugs on BLENREP: For combination therapies with bortezomib and dexamethasone or pomalidomide and dexamethasone, the PK profiles for belantamab mafodotin ADC and cys-mcMMAF were evaluated and compared with monotherapy data. The observed PK for belantamab mafodotin

ADC and cys-mcMMAF suggested lack of impact of bortezomib and dexamethasone or pomalidomide and dexamethasone on the PK of the ADC and cys-mcMMAF.

Effect of BLENREP on other drugs: For combination therapies with bortezomib and dexamethasone or pomalidomide and dexamethasone, the PK profiles for bortezomib and pomalidomide were evaluated in clinical trials and compared with historical data. The observed PKs for bortezomib and pomalidomide suggested lack of impact of belantamab mafodotin on the PK of the included combination therapies.

10. Clinical Pharmacology

10.1. Mechanism of Action

Belantamab mafodotin is an antibody-drug conjugate (ADC), consisting of a humanised IgG1 kappa monoclonal antibody conjugated with a microtubule inhibitor, mcMMAF. Belantamab mafodotin binds to the cell surface BCMA, a protein expressed on normal B lymphocytes and multiple myeloma cells and is rapidly internalised. Once inside the cell, the cytotoxic agent (cys-mcMMAF) is released disrupting the microtubule network, leading to cell cycle arrest and cell apoptosis. The belantamab antibody also enhances recruitment and activation of immune effector cells, killing cells by antibody-dependent cellular cytotoxicity and phagocytosis. Apoptosis induced by belantamab mafodotin is accompanied by markers of immunogenic cell death, which may contribute to an adaptive immune response to the target cells.

The target-specific and efficient mechanism of action of BLENREP, combined with bortezomib or pomalidomide, provides a unique and complementary mechanism of action, resulting in an additive or potentially synergistic effect which may translate into a deep and long-lasting response.

10.2. Pharmacodynamics

Exposure-Response Relationship

In combination therapy with bortezomib and dexamethasone or pomalidomide and dexamethasone, higher belantamab mafodotin (antibody drug conjugate, ADC) Cycle 1 exposure was associated with higher probability of response [e.g. very good partial response (VGPR)] and higher incidence of some safety adverse reactions (e.g. Grade ≥ 2 corneal examination findings).

Cardiac Electrophysiology

Belantamab mafodotin had no meaningful QTc prolongation (>10 ms) at the doses of 2.5 mg/kg once every 3 weeks, nor at 3.4 mg/kg once every 3 weeks.

10.3. Pharmacokinetics

Table 12 provides a summary of the pharmacokinetic parameters observed for belantamab mafodotin ADC across the pooled population of patients with multiple myeloma who have received at least 1 prior line of therapy in DREAMM-7. Table 13 provides a summary of the pharmacokinetic parameters observed for belantamab mafodotin ADC across the pooled population of patients with multiple myeloma who have received at least 1 prior line of therapy in DREAMM-8.

Table 12 DREAMM-7 Population Pharmacokinetic Analysis: Summary of belantamab mafodotin pharmacokinetic parameters in pooled population of patients with multiple myeloma who have received at least 1 prior line of therapy^a

	C_{max} (ug/mL)	T_{max} (hr)	t_½ (day)	AUC_{0-21 days} (ug•h/mL)	CL (L/day)	Vc (L)	Vp (L)
Belantamab mafodotin ADC	43.7 (22)	End of Infusion 0.5 (0.25, 0.5)	13.2 (26)	3950 (31)	0.901 (40)	4.26 (24)	6.42 (26)

	C_{max} (ng/mL)	T_{max} (hr)	t_½ (day)	AUC_{0-7 days} (ng•h/mL)	CL (L/hr)	Vc (L)	Vp (L)
Cys-mcMMAF	0.976 (45)	24 (0.5, 168)	5.53 (16.6)	94.2 (42)	25.7 (47)	11.6 (85)	377 (81)

ADC = antibody drug conjugate

^a Data are based on the final population PK model with data pooled from Phase 1 – 3 studies. ADC PK is a linear 2-compartment model with time-varying decrease in clearance, and cys-mcMMAF PK is a linear 2-compartment model linked to ADC, where the input rate of cys-mcMMAF included an arbitrary function of the drug-antibody ratio to approximate the proteolytic degradation of ADC. The non-compartmental analysis estimate of the half-life of belantamab mafodotin from sparsely sampled data is approximately 7 days. The non-compartmental analysis estimate of the half-life of cys-mcMMAF from sparsely sampled data is approximately 3 days (N=1). C_{max}, T_{max}, AUC provided at a dose level of 2.5 mg/kg and all PK parameters are summarized by the geometric mean (% CV) except T_{max} is summarized as a median (min, max) at the end of first 3-week interval. CL, Vc, Vp and t_{1/2} are dose independent parameters. Vc is central volume of distribution and Vp is peripheral volume of distribution.

Table 13 DREAMM-8 Population Pharmacokinetic Analysis: Summary of belantamab mafodotin pharmacokinetic parameters in pooled population of patients with multiple myeloma who have received at least 1 prior line of therapy^a

	C_{max} (ug/mL)	T_{max} (hr)	t_½ (day)	AUC_{0-28 days} (ug•h/mL)	CL (L/day)	Vc (L)	Vp (L)
Belantamab mafodotin ADC	47.1 (19)	End of Infusion 0.5 (0.48, 0.5)	13.2 (26)	4504 (25)	0.901 (40)	4.26 (24)	6.42 (26)

	C_{max} (ng/mL)	T_{max} (hr)	t_½ (day)	AUC_{0-7 days} (ng•h/mL)	CL (L/hr)	Vc (L)	Vp (L)
Cys-mcMMAF	0.933 (42)	24 (0.5, 168)	5.53 (16.6)	90.5 (41)	25.7 (47)	11.6 (85)	377 (81)

ADC = antibody drug conjugate

- a. Data are based on the final population PK model with data pooled from Phase 1 – 3 studies. ADC PK is a linear 2-compartment model with time-varying decrease in clearance, and cys-mcMMAF PK is a linear 2-compartment model linked to ADC, where the input rate of cys-mcMMAF included an arbitrary function of the drug-antibody ratio to approximate the proteolytic degradation of ADC. The non-compartmental analysis estimate of the half-life of belantamab mafodotin from sparsely sampled data is approximately 7 days. The non-compartmental analysis estimate of the half-life of cys-mcMMAF from sparsely sampled data is approximately 3 days (N=1). C_{max} , T_{max} , AUC provided at a dose level of 2.5 mg/kg and all PK parameters are summarized by the geometric mean (% CV) except T_{max} is summarized as a median (min, max) at the end of first 4-week interval. CL, Vc, Vp and $t_{1/2z}$ are dose independent parameters. Vc is central volume of distribution and Vp is peripheral volume of distribution.

Absorption

Maximum concentration for belantamab mafodotin ADC occurred at or shortly after the end of infusion while cys-mcMMAF concentrations peaked ~24 hours after dosing.

Accumulation of belantamab mafodotin ADC was minimal to moderate (Geometric means: 1.13 for C_{max} and 1.58 for AUC) as observed in clinical studies with a every 3 weeks dosing regimen.

Distribution

In vitro, cys-mcMMAF exhibited low protein binding (56–86% unbound) in human plasma.

Based on the population PK analysis, the combined geometric mean (geometric CV%) for steady-state volume of distribution parameter of belantamab mafodotin was 10.8 L (22%).

Metabolism

The monoclonal antibody portion of belantamab mafodotin is expected to undergo proteolysis to small peptides and individual amino acids by ubiquitous proteolytic enzymes. Cys-mcMMAF had limited metabolic clearance in human hepatic S9 fraction incubation studies.

Elimination

Based on the population PK analysis, the geometric mean (geometric CV%) belantamab mafodotin ADC initial systemic CL parameter was 0.901 L/day (40%), and the elimination half-life was 13 days (26%). Following treatment, steady-state CL parameter was 0.605 L/day (43%) or approximately 33% lower than initial systemic CL parameter with an elimination half-life of 17 days (31%).

Following intravenous administration of radioactive cys-mcMMAF to rats, approximately 83% of the radioactive dose was excreted in feces with 13% recovered in urine. In clinical studies, the fraction of cys-mcMMAF excreted in urine was not substantial (approximately 18% of the dose) after the Cycle 1 dose, with no evidence of other MMAF-related metabolites.

Linearity/non-linearity

Belantamab mafodotin exhibits approximately dose-proportional pharmacokinetics over the recommended dose range up to 4.6 mg/kg. In the population PK model, the dose-proportionality was observed in the C_{max} , AUC and C_{trough} parameters for ADC and cys-mcMMAF across the relevant dose range.

Special populations and conditions

- **Pediatrics:** No pharmacokinetic data are available in pediatric patients.
- **Geriatrics:** Based on a population of patients aged 32 to 89 years, age was not a significant covariate in population pharmacokinetics analyses with respect to all model parameters.
- **Renal Insufficiency:** In patients with severe renal impairment (eGFR: 15 – 29 mL/min), belantamab mafodotin C_{max} decreased by 23% and $AUC_{(0-tau)}$ decreased by 16% compared with

patients with normal or mild renal impairment (eGFR \geq 60 ml/min). For cys-mcMMAF, C_{max} and $AUC_{(0-168h)}$ decreased by 56% and 44%, respectively compared to patients with normal or mild renal impairment. Renal function (eGFR:12 to 150 mL/min) was not a significant covariate in population pharmacokinetic analyses with respect to all model parameters that included patients with normal renal function, mild, moderate or severe renal impairment, or kidney failure.

Belantamab mafodotin is not expected to be removed via dialysis due to molecular size. While free cys-mcMMAF may be removed via dialysis, cys-mcMMAF systemic exposure is very low.

- **Hepatic Insufficiency:** No formal studies have been conducted in patients with hepatic impairment. Hepatic function, as per National Cancer Institute Organ Dysfunction Working Group classification, was not a significant covariate in population pharmacokinetic analyses with respect to all model parameters that included patients with normal hepatic function, mild hepatic impairment (total bilirubin $>$ ULN to $\leq 1.5 \times$ ULN and any AST or total bilirubin \leq ULN with AST $>$ than ULN) or moderate hepatic impairment (total bilirubin $>$ $1.5 \times$ ULN to $\leq 3 \times$ ULN and any AST).
- **Body weight:** Body weight (37 to 170 kg) was a significant covariate in population pharmacokinetic analyses with respect to some model parameters of ADC (central volume of distribution, peripheral volume of distribution, clearance, and intercompartmental clearance), but this effect is not clinically relevant with the weight-proportional dosing regimen.

10.4. Immunogenicity

All therapeutic proteins have the potential for immunogenicity. The detection of antibody formation is highly dependent on the sensitivity and specificity of the assay. Additionally, the observed incidence of antibody (including neutralizing antibody) positivity in an assay may be influenced by several factors including assay methodology, sample handling, timing of sample collection, concomitant medications, and underlying disease. For these reasons, comparison of incidence of antibodies in the studies described below with the incidences of antibodies in other studies or to other products may be misleading.

The incidence of anti-belantamab mafodotin antibodies was consistently low in patients treated with belantamab mafodotin in combination therapies. There is also no observed clinical impact on pharmacokinetics, safety, and efficacy.

In the pivotal combination therapy studies (DREAMM-7 and DREAMM-8) and the combination therapy supportive study (DREAMM-6), 3% of patients (15/515) tested positive for treatment emergent anti-belantamab mafodotin antibodies. Two patients tested positive for neutralising anti-belantamab mafodotin antibodies.

11. Storage, Stability, and Disposal

Storage and Stability

Lyophilized powder

Store in the original container. Store in a refrigerator (2°C to 8°C). Do not freeze.

Reconstituted solution

The reconstituted solution can be stored for up to 4 hours at room temperature (20°C to 25°C) or

stored in a refrigerator (2°C to 8°C) for up to 4 hours. Discard if not diluted within 4 hours. Do not freeze.

Diluted solution

If not used immediately, the diluted solution can be stored in a refrigerator (2°C to 8°C) prior to administration for up to 24 hours. Do not freeze. If refrigerated, allow the diluted solution to equilibrate to room temperature prior to administration.

The diluted solution may be kept at room temperature (20°C to 25°C) for a maximum of 6 hours (including infusion time).

Disposal

Any unused medicinal product or waste material should be disposed of in accordance with local requirements.

12. Special Handling Instructions

In the absence of compatibility studies, the reconstituted concentrate and diluted solution for infusion must not be mixed with other medicinal products.

Please see [11 Storage, Stability and Disposal](#).


Part 2: Scientific Information

13. Pharmaceutical Information

Drug Substance

Non-proprietary name of the drug substance: belantamab mafodotin

Molecular mass: 152 kDa



Product Characteristics:

Belantamab mafodotin is an antibody-drug conjugate (ADC) with an afucosylated, humanised immunoglobulin G1 anti-BCMA monoclonal antibody conjugated by a protease-resistant maleimidocaproyl cysteine linker to a microtubule disrupting agent, monomethyl auristatin F.

14. Clinical Trials

14.1. Clinical Trials by Indication

DREAMM-7: BLENREP in combination with bortezomib and dexamethasone in adult patients with multiple myeloma who have received at least one prior therapy

Study Design

The efficacy and safety of BLENREP, in combination with bortezomib and dexamethasone (BVd), were compared to that of daratumumab, bortezomib and dexamethasone (DVd) in an open-label, randomized (1:1), phase 3, multi-centre study that enrolled patients with relapsed/refractory multiple myeloma (MM) who had received at least one prior therapy.

A total of 494 patients with MM were enrolled in DREAMM-7 and were included in the evaluation of efficacy. Key eligibility criteria included: a confirmed diagnosis of MM as defined by International Myeloma Working Group (IMWG) criteria, previous treatment with at least 1 line of MM therapy, documented disease progression during or after their most recent therapy, ECOG status of 0 – 2. Patients who were refractory or intolerant to daratumumab or bortezomib, or with prior exposure to anti-BCMA therapy were excluded. Patients with current corneal disease, except for mild punctate keratopathy, were excluded. Baseline demographics and characteristics were similar between treatment arms.

Treatment with BLENREP and daratumumab continued until disease progression, death, unacceptable toxicity, withdrawal of consent, or study end.

The primary endpoint was progression-free survival (PFS) as evaluated by a blinded Independent Review Committee (IRC) based on the IMWG response criteria for MM. Secondary endpoints included

overall survival (OS), overall response rate (ORR), duration of response (DoR) and minimal residual disease (MRD) negativity rate.

A summary of the study design and detailed demographics in DREAMM-7 are presented in [Table 14](#) and [Table 15](#).

Table 14 Summary of study design for clinical trials in adult patients with MM receiving BLENREP in combination with bortezomib and dexamethasone, who have received at least one prior therapy

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Age (range)	Sex
207503 (DREAMM-7) NCT04246047	Phase III, multicentre, open-label, randomized in 1:1 ratio	<p>BVd arm: BLENREP: 2.5 mg/kg (IV) every 3 weeks on day 1 of each cycle</p> <p>Bortezomib: 1.3 mg/m² (subcutaneously) on days 1, 4, 8 and 11 of cycles 1 to 8 (21-day cycles)</p> <p>Dexamethasone: 20 mg (IV or orally) on the day of, and the day after, bortezomib treatment</p>	BVd arm: n=243	BVd arm: 64.5 (34, 86)	BVd arm: 53% male; 47% female
		<p>DVd arm: Daratumumab: 16mg/kg (IV) in 21-day cycles: every week for cycles 1 to 3, every 3 weeks for cycles 4-8, every 4 weeks for cycles 9 and beyond</p> <p>Bortezomib: 1.3 mg/m² (subcutaneously) on days 1, 4, 8 and 11 of cycles 1 to 8 (21-day cycles)</p> <p>Dexamethasone: 20 mg (IV or orally) on the day of, and the day after, bortezomib treatment</p>	DVd arm: n=251	DVd arm: 63.6 (32, 89)	DVd arm: 57% male; 43% female

Table 15 Baseline demographics and disease characteristics in DREAMM-7

Baseline characteristics		BLNREP + bortezomib and dexamethasone (BVd) N = 243	Daratumumab + bortezomib and dexamethasone (DVd) N= 251
Age	Median (range)	65 (34, 86)	64 (32, 89)
	18 to 64 years, n (%)	121 (50)	126 (50)
	65 to <75 years, n (%)	85 (35)	95 (38)
	>=75 years, n (%)	37 (15)	30 (12)
Gender, n (%)	Male	128 (53)	144 (57)
	Female	115 (47)	107 (43)
Race, n (%)	White	206 (85)	203 (81)
	Asian	28 (12)	33 (13)
	Black	8 (3)	12 (5)
	Mixed	0	1 (<1)
ECOG PS at baseline, n (%)	0	121 (50)	112 (46)
	1	111 (46)	123 (50)
	2	10 (4)	11 (4)
R-ISS stage at screening, n (%)	I	102 (42)	103 (41)
	II	130 (53)	132 (53)
	III	9 (4)	14 (6)
	Unknown	2 (<1)	2 (<1)
Cytogenetics risk, n (%)	High-risk ^a	67 (28)	69 (27)
EMD present, n (%)	n (%)	13 (5)	25 (10)
Number of prior lines of therapy, n (%)	Median ^b , range	1.0 (1, 7)	2.0 (1, 7)
	1 line	125 (51)	125 (50)
	2 line	54 (22)	63 (25)
	3 line	34 (14)	36 (14)
	≥4 line	20 (12)	27 (11)
Prior therapies, n (%)	Proteasome Inhibitors	218 (90)	216 (86)
	Bortezomib	210 (86)	211 (84)
	Carfilzomib	31 (13)	35 (14)
	Ixazomib	13 (5)	11 (4)
	Immunomodulators	198 (81)	216 (86)
	Lenalidomide	127 (52)	130 (52)
	Thalidomide	121 (50)	144 (57)
Pomalidomide	25 (10)	19 (8)	
	Daratumumab	3 (1)	4 (2)
Refractory to prior therapies, n (%)	Proteasome Inhibitors	22 (9)	24 (10)
	Bortezomib	4 (2)	0
	Carfilzomib	12 (5)	17 (7)
	Ixazomib	7 (3)	8 (3)

Baseline characteristics		BLENREP + bortezomib and dexamethasone (BVd) N = 243	Daratumumab + bortezomib and dexamethasone (DVd) N= 251
	Immunomodulators	94 (39)	104 (41)
	Lenalidomide	79 (33)	87 (35)
	Thalidomide	16 (7)	22 (9)
	Pomalidomide	17 (7)	12 (5)
Prior ASCT, n (%)		164 (67)	173 (69)

ASCT = autologous stem cell transplantation; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EMD = Extramedullary disease; PI = proteasome inhibitor; R-ISS = Revised-International Staging System.

^a High-risk cytogenetic factors [positive for t (4;14), t (14;16), or 17p13del]

^b Mean prior lines of therapy was similar in the BVd (2.0) and DVd (1.9) groups. Median prior lines of therapy was calculated as 1.0 (BVd) and 2.0 (DVd) but given the near equal distribution by lines of therapy between groups, it should not be considered different.

Study Results

The study met its primary objective of demonstrating improvement in PFS. The findings were consistently observed in subgroups and supported by secondary endpoints.

At the first pre-planned interim analysis, the hazard ratio for OS was 0.57; 95% (CI: 0.40, 0.80) indicating a 43% reduction in the risk of death in favour of BVd. At this interim analysis OS data are immature based on an Information Fraction (IF) of 40% (141/355 events). The final analysis of OS will take place when 355 events for OS analysis have occurred.

The MRD-negativity rates were 24.7% and 9.6% in the BVd and DVd treatment arms, respectively. The median duration of response in patients who achieved at least a partial response was 35.6 months (95%CI: 30.5, NR) for patients receiving BVd compared to 17.8 months (95%CI: 13.8, 23.6) for patients receiving DVd.

Efficacy results are shown in [Table 16](#), [Figure 1](#) and [Figure 2](#).

Table 16 Efficacy of BLENREP in DREAMM-7

	BLENREP + bortezomib and dexamethasone (BVd) ^a N = 243	Daratumumab + bortezomib and dexamethasone (DVd) ^a N= 251
Progression-free survival (PFS)^b		
Number (%) of patients with event	91 (37)	158 (63)
Median in months (95% CI) ^c	36.6 (28.4, NR)	13.4 (11.1, 17.5)
Hazard ratio (95% CI) ^d	0.41 (0.31, 0.53)	
p-value ^e	<0.00001	

	BLENREP + bortezomib and dexamethasone (BVd)^a N = 243	Daratumumab + bortezomib and dexamethasone (DVd)^a N= 251
Overall survival (OS)^f		
Number (%) of patients with event	54 (22)	87 (35)
Hazard ratio (95% CI) ^d	0.57 (0.40, 0.80)	
Overall response rate (ORR)^{b,g} % (95% CI)	82.7% (77.4, 87.3)	71.3% (65.3, 76.8)
Stringent complete response (sCR), n (%)	34 (14)	13 (5.2)
Complete response (CR), n (%)	50 (20.6)	30 (12)
Very good partial response (VGPR), n (%)	76 (31.3)	73 (29.1)
Partial response (PR), n (%)	41 (16.9)	63 (25.1)

CI = Confidence interval; NR = Not Reached.

^a Efficacy data is based on the intent-to-treat (ITT) population.

^b Response was based on IRC per IMWG criteria.

^c By Brookmeyer and Crowley method.

^d Based on stratified Cox regression model.

^e One-sided p-value based on stratified log-rank test.

^f At Interim Analysis 1, stringent criteria for overall survival were not met; OS maturity was 29%. Follow-up is ongoing.

^g ORR: sCR+CR+VGPR+PR

Figure 1 Kaplan-Meier curve of progression free survival in DREAMM-7





Figure 2 Kaplan-Meier curve of overall survival in DREAMM-7



Dose delays and/or reductions were frequently required to manage adverse reactions including ocular adverse reactions. Among patients who experienced an ocular adverse reaction, 91% (190/209) continued treatment on or after the onset of the first event and received a median of 8 additional doses (range: 1 to 52). Permanent discontinuation due to ocular adverse reactions occurred for 9% of BLENREP treated patients. BLENREP dosing observed during DREAMM-7 is presented in [Table 17](#).

Table 17 Observed BLENREP dose delays and reductions in DREAMM-7

		Number of doses by time interval		
		0 to ≤6 months	>6 to ≤12 months	>12 months
Relative dose intensity per patient (%)	n	242	162	132
	Mean	75	63	39
	Median (IQR)	77 (55, 99)	68 (38, 76)	28 (18, 57)
Number of doses administered by dose level (%)	n	242	155	130
	2.5 mg/kg	768 (68)	198 (34)	201 (18)
	1.9 mg/kg	365 (32)	379 (66)	921 (82)
Time between doses per patient (weeks) ^a	n	231	130	124
	Mean	4.78	6.80	10.91
	Median (IQR)	3.6 (3, 6)	4.7 (3, 8)	9.5 (5, 15)

IQR = Interquartile range

^a Intervals for 0 to ≤ 6 months, > 6 to ≤ 12 months, and > 12 months, were calculated either by using days or days converted into months.

DREAMM-8: BLENREP in combination with pomalidomide and dexamethasone in adult patients who have received at least one prior therapy including lenalidomide

DREAMM-8 was an open-label, Phase III, multicentre study which evaluated the efficacy and safety of BLENREP in combination with pomalidomide and dexamethasone (BPd) compared with pomalidomide, bortezomib and dexamethasone (PVd) in patients with multiple myeloma (MM) who have received at least one prior therapy including lenalidomide.

A total of 302 patients with MM were enrolled in DREAMM-8 and were included in the evaluation for efficacy. Key eligibility criteria included: a confirmed diagnosis of MM as defined by IMWG criteria, previous treatment with at least 1 prior line of MM therapy, including lenalidomide, documented disease progression during or after their most recent therapy, and ECOG performance status of 0-2. Patients with prior exposure to BCMA-targeted therapies or pomalidomide and who were intolerant/refractory to bortezomib were excluded. Patients with current corneal disease except for mild punctate keratopathy were excluded. Baseline demographics and characteristics were similar between treatment arms.

Treatment in both arms continued until progressive disease, unacceptable toxicity, withdrawal of consent, initiation of another anticancer therapy, end of study or death.

The primary endpoint was PFS as evaluated by a blinded Independent Review Committee (IRC) based on the IMWG response criteria for MM. Secondary endpoints included overall survival (OS), overall response rate (ORR), duration of response (DoR) and minimal residual disease (MRD) negativity rate.

A summary of the study design and detailed demographics in DREAMM-8 are presented in [Table 18](#) and [Table 19](#).

Table 18 Summary of study design for clinical trials in adult patients with MM receiving BLENREP in combination with pomalidomide and dexamethasone, who have received at least one prior therapy including lenalidomide

Study #	Study design	Dosage, route of administration and duration	Study subjects (n)	Age (range)	Sex
207499 (DREAMM-8) NCT04484623	Phase III, multicentre, open-label, randomized in 1:1 ratio	<p>BPd arm: BLENREP: 2.5 mg/kg (IV) once on day 1 in cycle 1 (28-day cycle) followed by 1.9 mg/kg every 4 weeks on day 1 in cycle 2 onwards (28-day cycles)</p> <p>Pomalidomide: 4 mg (orally) administered on days 1 to 21</p> <p>Dexamethasone: 40 mg (orally) on Days 1, 8, 15, and 22 in all cycles (28-day cycles)</p>	BPd arm: n=155	BPd arm: 65.5 (40, 82)	BPd arm: 64% male; 36% female
		<p>PVd arm: Pomalidomide: 4 mg (orally) every 3 weeks on days 1 to 14 in all cycles (21-day cycles)</p> <p>Bortezomib: 1.3 mg/m² (subcutaneously) on days 1, 4, 8 and 11 of cycles 1 to 8, and on days 1 and 8 in cycle 9+ (21-day cycles)</p> <p>Dexamethasone: 20 mg (orally) on the day of, and the day after, bortezomib treatment</p> <p>Note: dexamethasone was reduced by half in patients aged 75 years and older for both arms</p>	PVd arm: n=147	PVd arm: 66.7 (34, 86)	PVd arm: 56% male; 44% female

Table 19 Baseline demographics and disease characteristics in DREAMM-8

Baseline Characteristics		BLNREP + pomalidomide and dexamethasone (BPd) N = 155	Pomalidomide + bortezomib and dexamethasone (PVd) N= 147
Age	Median (range)	67 (40, 82)	68 (34, 86)
	18 to 64 years, n (%)	64 (41)	53 (36)
	≥65 to <75 years, n (%)	72 (46)	59 (40)
	>=75 years, n (%)	19 (12)	35 (24)
Gender, n (%)	Male	99 (64)	82 (56)
	Female	56 (36)	65 (44)
Race ^a , n (%)	White	133 (86)	127 (87)
	Asian	20 (13)	17 (12)
	Native Hawaiian or Other Pacific Islander	1 (<1)	2 (1)
	Mixed race	1 (<1)	0
ECOG PS at baseline ^b , n (%)	0	79 (53)	85 (58)
	1	67 (45)	56 (39)
	2	4 (3)	5 (3)
ISS stage at screening, n (%)	I	93 (60)	85 (58)
	II	39 (25)	40 (27)
	III	22 (14)	22 (15)
	Unknown	1 (<1)	0
Cytogenetics risk, n (%)	High risk ^c	52 (34)	47 (32)
EMD present, n (%)		20 (13)	11 (7)
Number of prior lines of therapy, n (%)	Median, range	1.0 (1, 6)	1.0 (1, 9)
	1 line	82 (53)	77 (52)
	2 line	32 (21)	33 (22)
	3 line	22 (14)	15 (10)
	≥4 line	19 (12)	22 (15)
Prior Therapies, n (%)	Immunomodulators	155 (100)	147 (100)
	Lenalidomide	155 (100)	147 (100)
	Thalidomide	49 (32)	48 (33)
	Proteasome Inhibitors	140 (90)	136 (93)
	Bortezomib	134 (86)	130 (88)
	Carfilzomib	34 (22)	37 (25)
	Ixazomib	11 (7)	15 (10)
	Anti-CD38	38 (25)	42 (29)
Daratumumab	36 (23)	39 (27)	
Isatuximab	2 (1)	3 (2)	
Refractory to prior therapies, n (%)	Immunomodulators	127 (82)	111 (76)
	Lenalidomide	125 (81)	111 (76)
	Thalidomide	9 (6)	6 (4)

Baseline Characteristics		BLENREP + pomalidomide and dexamethasone (BPd) N = 155	Pomalidomide + bortezomib and dexamethasone (PVd) N= 147
	Proteasome Inhibitors	40 (26)	35 (34)
	Bortezomib	16 (10)	8 (5)
	Carfilzomib	18 (12)	23 (16)
	Ixazomib	8 (5)	11 (7)
	Anti-CD38	35 (23)	36 (24)
	Daratumumab	33 (21)	34 (23)
	Isatuximab	2 (1)	2 (1)
Prior ASCT, n (%)		99 (64)	82 (56)

ASCT = autologous stem cell transplantation; ECOG PS = Eastern Cooperative Oncology Group Performance Status; EMD = Extramedullary disease; ISS = International Staging System.

^a Percentages are out of 146 for PVd arm; the race of one patient is missing.

^b Percentage is out of the patients who were dosed. BPd n = 150 and PVd n = 145

^c High-risk cytogenetic factors [positive for at least one high risk abnormality: t (4;14), t (14;16), or 17p13del]

Study Results

The study met its primary objective of demonstrating improvement in PFS. The findings were consistently observed in subgroups and supported by secondary endpoints.

At the pre-planned first interim analysis, the estimated OS HR was 0.77 (95% CI:0.53, 1.14). At this analysis, OS data were immature based on an Information Fraction (IF) of 48% (105/217 events). The final analysis of OS will take place when 217 planned events for OS analysis have occurred.

The MRD-negativity rates were 23.9% and 4.8% in the BPd and PVd treatment arms, respectively. The median duration of response (in months) in patients who achieved at least a partial response was not reached (NR) (95% CI: 24.9, NR) for patients receiving BPd compared to 17.5 (95% CI: 12.1, 26.4) for patients receiving PVd.

Efficacy results are shown in [Table 20](#) and [Figure 3](#).

Table 20 Efficacy of BLENREP in DREAMM-8

	BLENREP + pomalidomide and dexamethasone (BPd) ^a N = 155	Pomalidomide + bortezomib and dexamethasone (PVd) ^a N= 147
Progression-free survival (PFS)^b		
Number (%) of patients with event	62 (40)	80 (54)
Median in months (95% CI) ^{c,d,e}	NR (20.6, NR)	12.7 (9.1, 18.5)
Hazard ratio (95% CI) ^f	0.52 (0.37, 0.73)	
p-value ^g	<0.001	

	BLNREP + pomalidomide and dexamethasone (BPd)^a N = 155	Pomalidomide + bortezomib and dexamethasone (PVd)^a N= 147
Overall response rate (ORR)^{b,h} (95% CI)	77% (70, 83.7)	72% (64.1, 79.2)
Stringent complete response (sCR), n (%)	14 (9)	4 (3)
Complete response (CR), n (%)	48 (31)	20 (14)
Very good partial response (VGPR), n (%)	37 (24)	32 (22)
Partial response (PR), n (%)	21 (14)	50 (34)

CI = Confidence interval; NR = Not Reached.

^a Efficacy data is based on the intent-to-treat (ITT) population.

^b Response was based on IRC per IMWG criteria.

^c By Brookmeyer and Crowley method.

^d Median follow-up of 21.8 months.


^e At the time of the data cut-off (29 JAN 2024).

^f Based on stratified Cox regression model.

^g One-sided p-value based on stratified log-rank test.

^h ORR: sCR+CR+VGPR+PR.

Figure 3 Kaplan-Meier curve of progression free survival in DREAMM-8



Dose delays and/or reductions were frequently required to manage adverse reactions including ocular adverse reactions. Among patients who experienced an ocular adverse event, 92% (120/131) continued treatment on or after the onset of the first event and received a median of 5 additional doses (range: 1 to 21). Permanent discontinuation of study treatment due to ocular events occurred for 9% of patients treated with BLENREP. BLENREP dosing observed during DREAMM-8 is presented in [Table 21](#).

Table 21 Observed BLENREP dose delays and reductions in DREAMM-8

		Number of doses by time interval		
		0 to ≤6 months	>6 to ≤12 months	>12 months
Relative Dose Intensity (%)	n	150	109	82
	mean	71	47	44
	median (IQR)	78 (48, 99)	35 (24,68)	37 (30, 47)
Number of doses administered by dose level (%)	n	150	104	77
	2.5 mg/kg	151 (26)	–	–
	1.9 mg/kg	415 (73)	235 (97)	267 (93)
	1.4 mg/kg	4 (<1)	7 (3)	19 (7)
Time between doses per patient (weeks) ^a	n	129	79	77
	mean	5.26	11.91	14.2
	median (IQR)	4.1 (4, 5)	11.8 (5, 16)	14.1 (10, 18)

IQR = Interquartile range

^b Intervals for 0 to ≤6 months, > 6 to ≤ 12 months, and > 12 months, were calculated either by using days or days converted into months.

16. Non-Clinical Toxicology

General Toxicology:

Belantamab mafodotin was evaluated in rats and monkeys in single dose toxicity studies (up to 100 mg/kg and 30 mg/kg, respectively) and in repeat dose toxicity studies of up to 13 weeks duration following IV administration (up to 30 mg/kg and 10 mg/kg, respectively) followed by an off-dose period of up to 12 weeks. The principal adverse findings (directly related to belantamab mafodotin) in the rat and monkey, at exposures ≥1.2 times of the recommended clinical dose of 2.5 mg/kg, were elevated liver enzymes sometimes associated with hepatocellular necrosis at ≥10 and ≥3 mg/kg, respectively, and increases in alveolar macrophages associated with eosinophilic material in the lungs at ≥3 mg/kg (rat only). Most findings in animals were related to the cytotoxic drug conjugate, the histopathological changes observed in the testes and lungs, were not reversible in rats.

Single cell necrosis in the corneal epithelium and/or increased mitoses of corneal epithelial cells was observed in rat and rabbit. Inflammation of the corneal stroma correlating with superficial haze and vascularisation was observed in rabbits. Belantamab mafodotin was taken up into cells throughout the body by a mechanism unrelated to BCMA receptor expression on the cell membrane.

Carcinogenicity/mutagenesis: Belantamab mafodotin was genotoxic in an *in vitro* micronucleus screening assay in human lymphocytes, consistent with the pharmacological effect of cys-mcMMAF-mediated disruption of microtubules causing aneuploidy.

No carcinogenicity or definitive genotoxicity studies have been conducted with belantamab mafodotin.

Reproductive and Developmental Toxicology: No animal studies have been performed to evaluate the potential effects of belantamab mafodotin on reproduction or development. The mechanism of action is to kill rapidly dividing cells which would affect a developing embryo which has rapidly dividing cells. There is also a potential risk of heritable changes via aneuploidy in female germ cells.

In rats, weekly dosing for 3 weeks at doses ≥ 10 mg/kg (approximately 4 times the recommended clinical dose) resulted in degeneration and atrophy of seminiferous tubules in the testes and luteinized nonovulatory follicles in the ovaries. Findings in females were reversible; findings in the testes were not reversible at the end of the 12-week recovery period with weekly dosing or when given every 3 weeks for 13 weeks at doses ≥ 10 mg/kg. In male monkeys, the highest dose tested of 10 mg/kg (approximately 4 times the recommended clinical dose) given weekly for 13 weeks resulted in seminiferous tubules degeneration in the testes that was fully reversed following the 12-week recovery period.

Patient Medication Information

READ THIS FOR SAFE AND EFFECTIVE USE OF YOUR MEDICINE

Pr **BLENREP**

belantamab mafodotin for injection

This patient medication information is written for the person who will be taking **BLENREP**. This may be you or a person you are caring for. Read this information carefully. Keep it as you may need to read it again.

This patient medication information is a summary. It will not tell you everything about this medication. If you have more questions about this medication or want more information about **BLENREP**, talk to a healthcare professional.

This medicine has been prescribed for you personally. Your cancer is being treated with **BLENREP** together with other drugs. Read the leaflets of the other drugs as well as this one. This will help you understand the information related to your treatment.

Serious warnings and precautions box

- **Eye-related issues**

BLENREP can cause changes to the surface of your eye which can result in changes in vision, blurred vision, and dry eyes. You should have an eye examination by an eye care professional before each dose of **BLENREP**. Your doctor may request additional eye tests while on treatment with **BLENREP**. If you have not had vision changes or other eye changes, during the first six doses of **BLENREP**, your doctor may reduce eye exams to approximately every three months with additional eye exams when needed. Even if your vision seems fine, it is important that you get your eyes checked during treatment with **BLENREP** because some changes can happen without symptoms and may only be seen on an eye examination.

Do not use contact lenses while you are receiving treatment unless instructed to do so by your eye care professional.

Your doctor will ask you to use eye drops called *preservative-free artificial tears* at least 4 times a day during treatment to moisten and lubricate your eyes. You should apply them as instructed.

Tell your doctor if you notice changes with your vision. Your doctor may reduce the dose or change the time between doses. Your doctor might also ask you to see an eye care professional.

What **BLENREP is used for:**

BLENREP is a prescription medicine used to treat a type of cancer called multiple myeloma in adults 18 years or older. **BLENREP** is given after you have tried one or more other treatments that were unsuccessful or when the cancer has come back.

Multiple myeloma is a cancer of plasma cells (a type of white blood cell in the bone marrow that produces antibodies).

How BLENREP works:

BLENREP contains the active substance, belantamab mafodotin, which is made up of two types of medicine that are attached to each other. One part is a type of medicine called a monoclonal antibody. The monoclonal antibody is connected to the other part which is an anticancer medicine that can kill multiple myeloma cells. In BLENREP, the monoclonal antibody, belantamab, is a protein designed to find the multiple myeloma cancer cells in your body and bind to them. Once attached to the cancer cells, the anticancer medicine is released to kill the cancer cells.

BLENREP will be given together with other anticancer medicines used to treat multiple myeloma:

- bortezomib and dexamethasone.
- pomalidomide and dexamethasone.

The ingredients in BLENREP are:

Medicinal ingredients: belantamab mafodotin.

Non-medicinal ingredients: citric acid monohydrate; disodium edetate dihydrate; polysorbate 80; trehalose dihydrate; trisodium citrate dihydrate.

BLENREP comes in the following dosage form:

BLENREP is provided as a powder in a single-use vial that is reconstituted and diluted for intravenous Infusion.

BLENREP is a white to yellow powder in a glass vial with a rubber stopper and a plastic removable cap.

Each carton contains one vial of 70 mg or 100 mg of belantamab mafodotin. After reconstitution, the solution for injection contains 50 mg belantamab mafodotin per mL.

Do not use BLENREP if:

- You are allergic to any of the ingredients in BLENREP.
- If you are not sure, talk to your doctor or nurse before you are given BLENREP.

To help avoid side effects and ensure proper use, talk to your healthcare professional before you take BLENREP. Talk about any health conditions or problems you may have, including:

- if you are pregnant, think you may be pregnant or are planning to have a baby, **tell your healthcare professional** before you are given this medicine.
- if you are a woman who could become pregnant, you must use effective contraception during treatment and for 4 months after your last dose of BLENREP. Your healthcare professional will ask you to take a pregnancy test before you start treatment with BLENREP.
- if you are a man who could father a child, you must use effective contraception during treatment and for 6 months after your last dose of BLENREP.

You must not breast-feed during treatment and for 3 months after your last dose of BLENREP. It is not known if the medicine passes into breast milk. Talk to your healthcare professional before you are given this medicine.

Other warnings you should know about:

Eye-related changes

- BLENREP can cause changes to the surface of your eye which can result in changes in vision, blurred vision, and dry eyes.
- You should have an eye examination by an eye care professional (for example ophthalmologist (eye doctor) or optometrist) before each dose of BLENREP or more frequently as clinically indicated. Your doctor may request additional eye tests while on treatment with BLENREP. If you have not had vision changes or other eye changes, during the first six doses of BLENREP, your doctor may reduce eye exams to approximately every three months with additional eye exams when needed.
- Your healthcare professional may request additional eye tests during the course of your treatment with BLENREP. Even if your vision seems fine, it is important that you get your eyes checked during treatment with BLENREP because some changes can happen without symptoms and may only be seen in an eye examination.
- Do not use contact lenses while you are receiving BLENREP unless instructed to do so by your eye care professional.
- Your doctor will ask you to use eye drops called preservative-free artificial tears at least 4 times a day during treatment to moisten and lubricate your eyes. You should apply them as instructed.
- Tell your healthcare professional if you notice changes with your vision. Your healthcare professional may reduce the dose or change the time between doses. Your doctor may ask you to see an eye care professional.
- Contact your healthcare professional if you have blurred vision or other eye changes.
- BLENREP can cause changes with vision that can affect your ability to drive or use machines. If you are experiencing changes in your vision, do not drive or use machines. Talk to your healthcare professional about this.
- Additional information on ocular adverse reactions and their management is available in educational materials for patients and prescribers. These educational materials are available upon request by contacting GSK Medical Information at 1-800-387-7374.

Abnormal bruising and bleeding

- BLENREP can decrease the number of blood cells called platelets which help to clot your blood.
- Symptoms of low platelet counts (thrombocytopenia) may include abnormal bruising under the skin, bleeding longer than usual after a blood test or cut to the skin, and bleeding from your nose or your gums or more serious bleeding.
- Your healthcare professional will ask you to have a blood test before you start treatment, and regularly during treatment with BLENREP, to check that your platelet levels are normal.
- Tell your healthcare professional if you notice abnormal bleeding or bruising, or any symptoms that worry you.

Infections

- BLENREP, in combination with bortezomib and dexamethasone or pomalidomide and dexamethasone, may increase the occurrence of infections. These infections could be severe or life-threatening. Tell your doctor right away if you develop fever, feel very tired, have a cough, or have flu-like symptoms.

Infusion-related reactions

- BLENREP is given by a drip (infusion) into a vein. Some people who receive infusions develop infusion-related reactions.
- If you have previously had a reaction to an infusion of BLENREP, or any other medicine: Tell your healthcare professional before you receive another infusion.

Lung problems (pneumonitis)

- Severe and life-threatening inflammation of the lungs has occurred in some people who received BLENREP. Possible symptoms of lung inflammation include shortness of breath, chest pain, new onset or worsening cough. Your healthcare professional may decide to hold or stop treatment with BLENREP if you have these symptoms.
- Tell your doctor if you develop any lung problems or any breathing-related symptoms that worry you.

Tell your healthcare professional about all the medicines you take, including any drugs, vitamins, minerals, natural supplements or alternative medicines.

How to take BLENREP:

BLENREP will be given to you by a healthcare professional who is experienced in cancer treatment.

Your healthcare professional will give you BLENREP as a drip into a vein (*intravenous infusion*) for about 30 minutes.

Before your infusion, you should apply lubricating and moistening eye drops (preservative-free artificial tears). You should continue to use the eye drops at least 4 times a day during your treatment with BLENREP.

Usual dose:

Your healthcare professional will decide on the correct dose of BLENREP for you. The dose is calculated based on your body weight.

Overdose:

BLENREP will be given by your healthcare professional. In the unlikely event that you are given too much (an overdose), your doctor will check you for side effects.

If you think you, or a person you are caring for, have taken too much BLENREP contact a healthcare professional, hospital emergency department, regional poison control centre or Health Canada's toll-free number, 1-844 POISON-X (1-844-764-7669) immediately, even if there are no signs or symptoms.

Missed dose:

It is very important to go to all your appointments, to make sure your treatment works. If you miss an

appointment to receive BLENREP:

- Contact your healthcare professional or hospital or clinic immediately to reschedule your appointment.

Possible side effects from using BLENREP:

Like all medicines, this medicine can cause side effects, although not everybody gets them. These are not all the possible side effects you may have when taking BLENREP in combination with bortezomib and dexamethasone or pomalidomide and dexamethasone. If you experience any side effects not listed here, tell your healthcare professional.

Infusion-related reactions: Some people may have allergic-like reactions when they receive an infusion. These usually develop within minutes or hours but may develop up to 24 hours after treatment. Symptoms include flushing, chills, fever, difficulty breathing, rapid heartbeat, drop in blood pressure. Get medical help immediately if you think you may be having a reaction.

In combination with bortezomib and dexamethasone

Very common (more than 1 in 10) side effects include: upper respiratory tract infections with cold or cold-like symptoms (cough, runny nose or sore throat); fever; weakness and fatigue from low red blood cell count (anemia); infections from low white blood cell count (neutropenia, lymphopenia, and leukopenia); abnormal liver enzyme levels which may be a sign of liver problems (alanine aminotransferase, aspartate aminotransferase, gamma glutamyltransferase); diarrhea; feeling tired (fatigue); nausea.

Refer to the Serious Side Effects table below if you experience eye-related side effects.

Common (up to 1 in 10) side effects include: eye-related issues including tear production (lacrimation), double vision (diplopia), itchy eyes (eye pruritus), discomfort in the eye; foamy, frothy or bubbly-looking urine which may be a sign of high level of protein in your urine (albuminuria); vomiting; abnormal levels of creatine phosphokinase; infusion-related reactions.

Uncommon (up to 1 in 100) side effects include: eye sores, possibly with infection (infective keratitis).

In combination with pomalidomide and dexamethasone

Very common (more than 1 in 10) side effects include: upper respiratory tract infections with cold or cold-like symptoms (cough, runny nose or sore throat); feeling tired (fatigue); fever; weakness and fatigue from low red blood cell count (anemia); abnormal liver enzyme levels which may be a sign of liver problems (alanine aminotransferase and aspartate aminotransferase); diarrhea; nausea.

Refer to the Serious Side Effects table below if you experience eye-related side effects.

Common (up to 1 in 10) side effects include: infections from low white blood cell count (lymphopenia, and leukopenia); abnormal liver enzyme levels which may be a sign of liver problems (gamma glutamyltransferase); eye-related issues including tear production (lacrimation), double vision (diplopia), itchy eyes (eye pruritus), eye sores, possibly with infection (corneal ulcers including infective keratitis and ulcerative keratitis), discomfort in the eye; vomiting; infusion-related reactions; foamy, frothy or bubbly-looking urine which may be a sign of high level of protein in your urine (albuminuria).

For both combinations

Serious side effects and what to do about them

Frequency/Side Effect/Symptom	Talk to your healthcare professional		Get immediate medical help
	Only if severe	In all cases	
Very common			
Eye-related changes: changes to the surface of your eye, blurred vision, dry eyes, feeling of something in your eye (foreign body sensation in eyes), eye irritation, sensitivity to light (photophobia), eye pain, decreased vision, and changes with vision.		✓	
Infection of the lungs (pneumonia): fever, trouble breathing, chest pain, and new onset or worsening cough.		✓	✓
Low platelet counts (thrombocytopenia): abnormal bruising under the skin, bleeding longer than usual after a blood test or cut to the skin, and bleeding from your nose or your gums or more serious bleeding.		✓	✓
Unknown			
Lung problems (pneumonitis): trouble breathing, chest pains and dry cough, due to inflammation of the lungs.		✓	✓

If any of the side effects listed becomes severe or troublesome symptom, or if you notice any side effect that is not listed here or becomes bad enough to interfere with your daily activities, tell your healthcare professional.

Reporting side effects

You can report any suspected side effects associated with the use of health products to Health Canada by:

- Visiting the Web page on Adverse Reaction Reporting (canada.ca/drug-device-reporting) for information on how to report online, by mail or by fax; or
- Calling toll-free at 1-866-234-2345.

NOTE: Contact your healthcare professional if you need information about how to manage your side effects. The Canada Vigilance Program does not provide medical advice.

Storage:

It is unlikely that you will be asked to store BLENREP yourself. It will be stored in the hospital or clinic where it is given to you.

Store in a refrigerator (2°C to 8°C) in its original package. Do not freeze. Keep out of reach and sight of children.

Do not use this medicine after the expiry date which is stated on the label and carton after EXP. The expiry date refers to the last day of that month.

If you want more information about BLENREP:

- Talk to your healthcare professional
- Find the full product monograph that is prepared for healthcare professionals and includes the Patient Medication Information by visiting the Health Canada Drug Product Database website ([Drug Product Database: Access the database](#)); the manufacturer's website www.gsk.ca or by calling 1-800-387-7474.

This leaflet was prepared by GlaxoSmithKline Inc.

Date of Authorization: September 2025

© 2025 GSK group of companies or its licensor

Trademarks are owned by or licensed to the GSK group of companies